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ABSTRACT 
Posttraumatic stress disorder (PTSD) is a trauma and stressor-related disorder that 
occurs after exposure to a traumatic event. Veterans are at the greatest risk of developing 
PTSD. Although benzodiazepines are not recommended for the treatment of PTSD, they 
are still commonly prescribed to veterans. 
The overall distribution of therapies in the 1,134,201 cohort with PTSD is similar 
to that outlined in the 2010 Veterans Affairs Posttraumatic Stress Disorder Clinical 
Practice Guidelines. However, after the first-line psychotherapies and selective serotonin 
reuptake inhibitors (SSRIs), the not recommended benzodiazepines (7.07%) and atypical 
antipsychotics (7.53%) have the highest prevalence. The third most frequent overlapping 
therapy includes benzodiazepines in conjunction with SSRIs, although this percentage is 
only 0.49. 
In order to evaluate the association between benzodiazepines and health 
outcomes, 1:2 propensity score (PS) matching was employed to create a balanced cohort. 
Plots of standardized differences and distributions of propensity scores indicated that 1:2 
PS matching eliminated observable differences (in confounders and risk factors) between 
benzodiazepines users and nonusers. The final cohort included a total of 81,831 
benzodiazepine users and 161,662 nonusers for a total size of 242,493 veterans with 
PTSD. 
Generalized linear models and Cox proportional hazards models were used to 
assess health outcomes. Other than substance abuse outpatient visits (which was higher 
but statistically insignificant), benzodiazepine users had significantly higher incidence 
rate ratios for all health care visits. This includes hospitalizations (1.27), ED (1.16), 
general outpatient (1.18), total mental outpatient (1.37), and mental outpatient visits 
(1.48). With an outcome of suicide as cause of death, the statistically significant hazard 
ratio between benzodiazepine users and nonusers is 2.73, thus demonstrating significant 
elevation in the risk of suicide. 
The overall evidence from this study reveals that benzodiazepines are not 
uncommonly prescribed for patients with PTSD and that they are associated with greater 
health care utilization and suicide outcomes. Most importantly, this study strengthens the 
evidence against the use of benzodiazepines in veterans with PTSD and that clinicians 
should consider the benefits and risks – especially the almost three-fold increase in 
suicide death – when ultimately prescribing this pharmacotherapy. 
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Posttraumatic stress disorder (PTSD) was officially established as an anxiety 
disorder in 1980.1 Since that time, PTSD has been reclassified as a trauma and stressor- 
related disorder after exposure to a traumatic event that includes a disturbance duration of 
at least one month and clinically significant distress or impairment in occupational, 
social, or other critical areas of functioning.1 In 2013, PTSD diagnostic criteria were 
further revised in the DSM-5.2 Overall, in order to be currently diagnosed with PTSD, an 
individual must be exposed to a traumatic event that results in a cluster of symptoms, 
have negative self-worth, and serious impairment in occupational, social, or other areas 
of functioning that stems from the traumatic experience. (Appendix A) 
   The criterion of postexposure fear, helplessness, or horror is no longer included 
because it has been shown that the absence or prevalence of these emotions had no effect 
on PTSD prevalence.2 Furthermore, PTSD is no longer classified as an anxiety disorder 
but rather as a trauma and stressor-related disorder.2 A traumatic event is defined as 
exposure to actual or threatened death, serious injury, or sexual violence in at least one of 
the four following ways2: 
2 
1. Directly experiencing the traumatic event.
2. Witnessing the event in person as it occurred to others.
3. Learning that the traumatic event occurred to a close family member or close
friend.
4. Experiencing repeated or extreme exposure to aversive details of the traumatic
event.
The second criterion concerns the presence of one of the following intrusion symptoms 
after the traumatic event2: 
1. Recurrent, involuntary, and intrusive distressing memories of the traumatic
event.
2. Recurrent distressing dreams in which the content of the dream are related to the
traumatic event.
3. Dissociative reactions such as flashbacks in which the individual feels or acts as
if the traumatic event is recurring.
4. Intense or prolonged psychological distress at exposure to cues that resemble or
symbolize an aspect of the traumatic event.
5. Marked physiological reactions to cues that resemble or symbolize an aspect of
the traumatic event.
The third criterion concerns the avoidance of stimuli associated with the traumatic event 
after the event occurs and includes at least one of the following2: 
1. Avoidance of or efforts to avoid distressing memories, thoughts, or feelings
about or closely associated with the traumatic event.
2. Avoidance of or efforts to avoid external reminders that evoke distressing
3 
memories, thoughts, or feelings about or closely associated with the traumatic 
event. These external reminders can include people, places, conversations, 
activities, objects, and situations. 
The fourth criterion concerns negative alterations in cognition and mood associated with 
the traumatic event after the event occurs and includes at least two of the following2: 
1. Inability to remember an important aspect of the traumatic event.
2. Persistent negative beliefs and expectations about oneself, others, or the world.
3. Persistent, distorted cognitions about the cause or results of the traumatic event
that lead the individual to blame himself/herself or others.
4. Persistent negative emotional state. This includes fear, horror, guilt, shame, or
anger.
5. Distinctly diminished interest or participation in significant activities.
6. Feelings of estrangement or detachment from others.
7. Persistent inability to experience positive emotions. This includes satisfaction,
happiness, or loving feelings.
The fifth criterion concerns alterations in arousal and reactivity associated with the 
traumatic event after the event occurs and includes at least two of the following2: 
1. Angry outbursts and irritable behavior with little or no provocation.
2. Self-destructive or reckless behavior.
3. Hypervigilance.
4. Exaggerated startle response.
5. Problems with concentration.
6. Sleep disturbance that includes difficulty falling asleep, staying asleep, or
4 
restless sleep. 
     The sixth criterion is a disturbance duration longer than one month.2 The seventh is 
that the disturbance causes clinically significant distress or impairment in occupational, 
social, or other important areas of functioning.2 The final criterion is that the disturbance 
must not be attributable to the physiological effects of a substance or another medical 
condition.2 
Risk Factors 
Risk factors for PTSD include psychosocial, genetic, and biological components.1 
There are a variety of psychosocial risk factors in the general population; there is evidence 
that female gender, younger age at the time of trauma exposure, minority racial/ethnic 
status, lower socioeconomic status, lower education, and lower intelligence all serve as risk 
factors for PTSD.2,3,4 Crime, rape, combat, childhood abuse/neglect, sexual molestation, 
and physical assault are associated with a high probability of lifetime PTSD.5 
Approximately 30% of PTSD cases among men are attributable to combat while almost 
half of all cases among women are attributable to sexual violence.5 Sudden unexpected 
death accounts for approximately 30% of all cases of PTSD.5 
A meta-analysis examined psychosocial risk factors in the military population.6 
Gender, race, and education are pretrauma sociodemographic factors were all found to be 
associated with PTSD in military personnel and veterans.7 Females, non-white military 
persons, and service members with lower levels of education are more likely to develop 
PTSD.7 Military rank, branch of service, occupation, cumulative length of deployments, 
and number of deployments are important military characteristics that contribute the 
development of PTSD among combat soldiers who returned from Vietnam, the Persian 
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Gulf, Iraq, and Afghanistan.8 Nonofficers, army service, combat specialization, high 
numbers of deployments, and longer cumulative length of deployment are associated with 
PTSD.8 More adverse life events, prior trauma exposure, and prior psychological problems 
are also pretrauma factors that increased risk for PTSD in the military population.9 A 
number of variables in the trauma period also increased the risk for PTSD. These include 
increased combat exposure, discharging a weapon, witnessing someone being wounded or 
killed, severe trauma, and deployment-related stressors.10 Deployment related stressors 
include excessive heat or cold, concerns or problems with family members back home, 
problems with leadership, lack of privacy, and boredom.10 Finally, with respect to post- 
trauma, a lack of postdeployment social support and unemployment increased the risk for 
PTSD among veterans who served in Iraq and Afghanistan from 2002-2007.10 
Risk factors for PTSD also include genetic components. Family studies have shown 
that offspring of parents with PTSD are more likely to develop PTSD themselves when 
compared to offspring of parents without PTSD.11,12,13 Twin studies of PTSD have shown 
that exposure to traumatic events is influenced by genetic factors; these studies have also 
shown that PTSD is inheritable.14,15 In addition, both twin and family studies suggest that 
genetic influences on PTSD overlap with other mental disorders.11,12,13,14,15 The majority of 
genes that affect risk for PTSD also influence risk for other psychiatric disorders and vice 
versa. For example, genetic influences common to panic disorder and generalized anxiety 
disorder symptoms account for about 60% of the genetic variance in PTSD.1 No robust 
genetic predictors of PTSD have been identified using genetic association studies.16,17,18 
Serotonin transporter polymorphism, 5-HTTLPR, is one genetic variant that has been 
examined in multiple studies, but with conflicting results.16,17,18 
6 
Finally, there are a number of potential biological risk factors for PTSD.19 These 
include increased amygdala sensitivity, volume loss in the anterior cingulate cortex, and 
low levels of cortisol.19 However, whether these brain abnormalities are risk factors for 
PTSD or markers of the disorder is still uncertain.19 The amygdala mediates both stress 
response and emotional learning. Studies show patients with PTSD have increased 
amygdala responses to stressful scripts, trauma reminders, and general emotional stimuli 
that are not trauma-related.19 The amygdala is also sensitized to the presentation of 
subliminally threatening cues in patients with PTSD. A second potential biological risk 
factor involves the medial prefrontal cortex (PFC).19 The medial PFC consists of the 
anterior cingulate cortex (ACC), subcallosal cortex, and the medial frontal gyrus.19 
Through its connection with the amygdala, the medial PFC mediates stress response, 
emotional reactivity, and extinction of conditioned fear.19 Patients with PTSD exhibit 
decreased volumes of the frontal cortex, including reduced ACC volumes, which are a 
measure of brain size.19 This reduction in volume has been associated with PTSD symptom 
severity.19 Extinction of conditioned fear is also associated with reduced ACC volumes, 
which provides a biological correlate for imprinted traumatic memories in PTSD.19 Finally, 
both civilian and combat-related PTSD are associated with low levels of cortisol, a 
glucocorticoid secreted by the hypothalamic-pituitary-adrenal HPA axis. This stems from 
abnormal regulation of the HPA axis. In turn, low levels of cortisol lead to abnormal stress 
reactivity and fear processing in general.19 While it is well documented that individuals 







The noradrenergic, serotonergic, endogenous cannabinoid, opioid systems, and 
hypothalamic-pituitary adrenal axis all play a role in the development of PTSD.13,14 
Alterations in noradrenergic receptor activity, serotonergic receptor density, and 
endocannabinoid (eCB) receptors are linked to specific PTSD symptoms.6,20 Dynorphin 
opioid receptor signaling in response to stress can lead to anxious behaviors such as 
PTSD.19 Finally, increased levels of stress result in increased levels of corticotropin- 
releasing factor and abnormalities of the hypothalamic-pituitary adrenal axis, both of which 
are present in PTSD patients.20 
The noradrenergic system consists of adrenoreceptors (AR), a group of G protein- 
coupled receptors with alpha 1, alpha 2, and beta subtypes. The AR system stimulates 
central nervous system activity and sympathetic autonomic responses. The AR system 
plays a role in PTSD because it influences amygdala functioning and associated fear 
signaling.20 Increased noradrenaline activity leads to impaired medial prefrontal cortex 
functioning and fear extinction.20 This explains subsequent increases in anxiety and PTSD 
symptom severity. A potential noradrenaline target is the noradrenaline transporter 
(NET).20 The NET is also part of the noradrenergic system.20 The NET acts as a 
noradrenaline plasma membrane monoamine transporter, maintains presynaptic 
noradrenaline storage, and regulates dopamine uptake. As shown in Figure 1, the NET has 
high concentrations in the frontal cortex, hippocampus, amygdala, thalamus, and cerebellar 
cortex.20 There is decreased NET availability in patients with PTSD.6 
Serotonergic (5-HT) receptors are another neurobiological system involved in the 




coupled receptors involved in cognition, emotional processing, and behavioral regulation.20 
Fear regulation and threat responsiveness have been linked to 5-HT signaling in the 
amygdala.21 5-HT receptors can selectively induce anxiety attacks and trauma-related 
flashbacks in individuals with PTSD. The 5-HT 1A and 5-HT 1B receptors have been 
specifically identified in the study of stress disorders.21 5-HT 1A receptors have the highest 
density in the raphe nuclei, hippocampal formation, hypothalamus, and insula, temporal, 
cingulate, and ventral prefrontal cortices (Figure 1). Neuropathological abnormalities 
exhibited in limbic and paralimbic cortical areas, such as reduced cortex volume, reduced 
synaptic proteins, may be attributed to impaired 5-HT 1A receptor functioning; this 
impairment induces increased anxiety and fear responses. The 5-HT 1B receptors have the 
highest density in striatum, pallidum, nucleus acumbens, substantia nigra, and the ventral 
tegmental area (Figure 1). Alterations in 5-HT 1B receptor density have been shown to be 
linked to specific PTSD symptoms such as increased re-experiencing, numbing, and 
anxious arousal symptoms.20 The eCB, through the cannabinoid receptors CB 1 and CB 2, 
play an integral role in the development and function of the PTSD circuit, particularly in 
stress response.20 The CB 1 receptors play a specific and primary role in the behavioral 
consequences of stress exposure.6 CB 1 are found in high density throughout the forebrain 
limbic structures and modulate a plethora of behaviors, including mood, anxiety, stress, 
memory, learning, and extinction of fear. Alteration or disruption of CB 1 signaling results 
in heightened anxiety and depression.20 
The opioid system is also implicated in the development of PTSD.20 Opioid 
 
receptors are G protein-coupled receptors and are classified into the encephalin, dynorphin, 




density levels in a ventral medial, prefrontal, cortex-hippocampal-limbic circuit. 
Dynorphin opioid receptor signaling in response to stress can lead to persistent depressive 
and anxious behaviors, important components of PTSD.1 
The HPA axis is a neurocircuit involved with stress response. The HPA axis ties 
the central nervous system to the endocrine system and aids with adaptation to stress, 
maintenance of homeostasis, and baseline functioning.20 Corticotropin-releasing factor 
(CRF) is a neuronal signaling molecule produced by cells in the hypothalamus in response 
to stress. CRF receptors consist of the CRF-1 and CRF-2 subtypes. Increased levels of CRF 
activate the HPA axis and lead to increased levels of cortisol. These high levels of cortisol 
facilitate encoding of traumatic memory and enduring anxiety effects through these CRF 
receptors. PTSD patients exhibit higher cerebrospinal fluid levels of CRF along with 
abnormalities in the HPA axis system such as a dysregulation of the pituitary adenylate 




Estimates of the lifetime prevalence of PTSD have been consistent since the 
advent of the Diagnostic and Statistical Manual of Mental Disorders-III-R (PTSD 
diagnosis in 1987).1 In the United States, several studies have yielded a lifetime DSM-III- 
R prevalence ranging from approximately 8.0% to 12.0%.22,23,24 Prevalence differs by 
gender as well. For men, DSM-III-R prevalence ranged from 5.0% to 6.0% while for 
women this prevalence ranged from 10.0% to 11.0%.22,23,24 The most recent data in the 
United States are from the National Comorbidity Replication Survey (NCS-R), which 




prevalence of DSM-IV PTSD among adult Americans is 6.8%.24 The lifetime prevalence 
of PTSD among adult men is 3.6% and among adult women is 9.7%.24 In a recent survey 
of 27 countries, the highest lifetime prevalence of PTSD outside the United States was in 
Ukraine (4.8%) and New Zealand (6.1%).1 Furthermore, high rates of lifetime PTSD 
have been found in many postconflict settings. This includes PTSD rates of 16% in 
Ethiopia, 18% in Gaza, 28% in Cambodia, and 37% in Algeria.1 Among Operation 
Enduring Freedom/Operation Iraqi Freedom veterans, those with PTSD were three times 
more likely to report hopelessness or suicidal ideation than those without PTSD.25 
Expressions of hopelessness and thoughts of committing suicide are often used as 
behavioral markers for increased suicide risk.26 
Chronic PTSD is an episode of PTSD that lasts one year or longer and is not 
currently recognized as a distinct clinical diagnosis in the DSM-V.1 PTSD fails to remit 
even after many years for more than one-third of individuals who develop it.22 The 
Detroit Area Survey of Trauma in young adults showed that after trauma exposure, 22% 
of women developed chronic PTSD compared to 6% of men.27 Past-year prevalence is 
prevalence of PTSD within the past 12 months.1 In 2005, the past-year prevalence of 
DSM-IV PTSD was 3.5% in the United States, higher than in any other country.22 Past- 
year prevalence estimates were less than 1% in many other countries, including Mexico, 
Nigeria, Germany, Italy, Spain, Israel, China, and Japan.1 Twelve month prevalence rates 
have also been shown to decline with age, ranging from 4.7% in those aged 55-64 to 
0.6% in those aged 65-74 to 0.1% in those aged 75-84.1 
The conditional risk of PTSD is defined as the probability of developing PTSD 




exposed men developed DSM-IV PTSD.24 In a DSM-V field trial, the conditional risk of 
PTSD ranged from 10.3% to 11.7%.28 Conditional risk for PTSD may decline with age. 
For childhood events, lifetime conditional rates are approximately 35% for women and 
10% for men.28 For adulthood events, conditional rates are approximately 25% for 
women and 15% for men.28 
The prevalence of PTSD is much higher in veterans compared to other 
subpopulations.1 This is because veterans are at an elevated risk for exposure to trauma.1 
The 2001 Veterans Affairs (VA) National Survey of Veterans was a nationally 
representative survey of over 20,000 veterans enrolled in Veterans Health Administration 
(VHA) system.29 Across wars and eras, 39% of VHA users (41% of men and 12% of 
women) reported exposure to combat and 36% reported exposure to the dead, dying, or 
wounded.29 During the wars in Afghanistan and Iraq, with a prevalence of 50% among 
VHA users, the most frequent type of exposure was having a friend wounded or killed, 
with 50% of VHA users experiencing that.29 Other types of exposure included seeing 
dead or seriously injured noncombatants (45%), witnessing an accident resulting in 
serious injury or death (45%), smelling decomposing bodies (37%), being physically 
moved or knocked over by an explosion (23%), having a blow to the head (18%), 
engaging in hand-to-hand combat (10%), and being responsible for the death of a civilian 
(5%).29 
One study investigated the prevalence of PTSD in a sample of Army service 
members three to fourth months postdeployment; approximately 12% of those returning 
from Afghanistan and 18% of those returning from Iraq met the criteria for PTSD using 




symptoms of PTSD.30 It is one of the most commonly-used self-report measures of PTSD 
but is not consistently used throughout the VA.31 There are two versions of the PCL; the 
PCL-M is specific to PTSD caused by military experiences and the PCL-C is applied 
generally to any traumatic event.31 The PCL consists of 17 items that correspond to DSM- 
IV PTSD symptoms. Respondents are asked to rate the degree [(1 (not at all) to 5 
(extremely)] to which they were bothered by symptoms in the past month.31 The PCL is 
both valid and reliable.31 Another study found that 5% of Army and Marine service 
members returning from Iraq and 10% of Army and Marine service members returning 
from Afghanistan screened positive for PTSD 2 weeks after deployment.30 The Primary 
Care PTSD Screen (PC-PTSD), a four-item screen, was used to identify veterans with 
PTSD.30 The PC-PTSD consists of four yes/no questions on nightmare, avoidance, 
hyperarousal, and numbing symptoms. The results of the PC-PTSD are considered 
positive if a patient answers yes to any three items.30 In a RAND survey of almost 2000 
individuals who served in Afghanistan and Iraq, approximately 14% of all veterans met 
criteria for PTSD in the past 30 days using the PCL Checklist.32 Finally, in a VA national 
sample of over 100,000 veterans who served in Afghanistan and Iraq, approximately 13% 
of veterans were diagnosed with PTSD.33   PTSD was diagnosed using ICD-9 codes, and 
the majority of mental health diagnoses (60%) occurred in nonmental health settings, 
particularly in primary care (42%).33 Finally, as will be described in further detail, 

















Table 1. Pharmacotherapies Used for Treatment of PTSD1,21,36 
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Cognitive behavioral therapy (CBT) is the most effective treatment for PTSD.34 
CBT involves talking with a therapist once a week, typically for up to four months.34 The 
two different types of CBT that are recommended for the treatment of PTSD include 
cognitive processing therapy (CPT) and prolonged exposure (PE).34 CPT focuses on 
examining distressing thoughts and memories of a traumatic event.34 CPT allows 
individuals to develop skills to handle these distressing thoughts.34 Through examining, 
challenging, and changing thoughts, individuals can change the way they feel about the 
traumatic event.34 CPT has four components:35 
1. Learning about PTSD symptoms and how treatment can be of assistance. 
 
2. Becoming aware of thoughts and feelings. 
 
3. Cognitive restructuring that involves learning skills to challenge an 
individual’s thoughts and feelings. 
4. Understanding common changes in beliefs that occur after going through a 
traumatic event. 
CPT is widely supported in treatment guidelines.12,15-17, 36-37 In a randomized controlled a 




better improvements in PTSD and comorbid symptoms than the waitlist control group.19 
Another randomized controlled trial showed that active duty military personnel treated 
with CPT experienced a greater reduction in PTSD symptom severity compared to those 
who used group present-centered therapy; only veterans treated with CPT experienced a 
reduction in depression.36 Furthermore, a second randomized controlled trial conducted in 
active-duty service members showed that veterans treated with either individual or group 
CPT significantly improved in PTSD severity, depression, and suicidal ideation.37 
While CPT focuses on examining distressing thoughts and feelings, PE helps 
individuals with PTSD via habituation to fear and anxiety.34 Prolonged exposure to 
thoughts, feelings, and situations that an individual has been avoiding helps him or her 
learn that reminders of the trauma do not have to be avoided.34 In PE, an individual 
identifies situations he or she has been avoiding and repeatedly confronts them until 
distress decreases.34 The focus of PE is on the management of reactions to stressful 
memories.16 Similar to CPT, PE has four components34: 
1. Learning about PTSD symptoms and how treatment can be of assistance. 
 
2. Breathing training to help an individual relax and manage distress. 
 
3. Real world exposure to fear- or anxiety-provoking situations to reduce distress 
that contributes to avoidance of these situations. 
4. Repeatedly reliving the trauma via imaginal exposure to reduce distress that 
contributes to avoidance of memories about the trauma. 
There is strong evidence for exposure therapy, of which PE has received the most 
attention.7-12 In a multisite randomized controlled trial, veterans and activity duty 




to those who received present-centered therapy.13 In addition, in a randomized controlled 
trial of female assault survivors, PE alone and PE plus cognitive restructuring reduced 
PTSD and depression relative to a waitlist control (individuals who were waitlisted to 




Trauma-focused psychotherapy is the recommended first-line treatment for PTSD 
and includes CPT and PE.34 While psychotherapy is the preferred, first-line treatment for 
PTSD, pharmacotherapy is also an important treatment option.38 The selective serotonin 
reuptake inhibitors (SSRIs) sertraline and paroxetine are approved by the FDA for the 
treatment of PTSD.38 A 2008 meta-analysis included fourteen randomized clinical trials 
that investigated different SSRIs - sertraline, fluoxetine, paroxetine, and citalopram39; 
seven demonstrated a positive outcome benefit while seven demonstrated no benefit in the 
Clinician-Administered PTSD scale (CAPS) score, which measures the frequency and 
intensity of PTSD symptoms.40-53 Two large randomized controlled trials investigated the 
serotonin-norepinephrine reuptake inhibitors (SNRI) venlafaxine.43,54 Both studies had 
dropout rates exceeding 30% and showed very small, albeit statistically significant changes 
in CAPS.43,54 The alpha-adrenergic blocker prazosin was effective for combat-related 
nightmares and sleep disturbance in veterans in two small studies.55,56 
A 2013 meta-analysis found a number of effective treatments which reduced total 
PTSD symptom and severity scores, measured by CAPS.57 Effective pharmacotherapies 
included sertraline, paroxetine, fluoxetine, venlafaxine, and risperidone.
40,43,46,52,58 CAPS- 




symptoms, questions cover onset and duration of symptoms, subjective distress, impact of 
symptoms on social and role functioning, and overall PTSD severity.59,60 The CAPS-5 total 
severity score is calculated by summing up the individual item severity scores for 
symptoms corresponding to given cluster.59,60 Item scores range from 0-4 and total scores 
range from 0-80.57,58 A 2014 Cochrane review found that of all the medication classes, 
evidence of treatment efficacy was most convincing for SSRIs.59,60 Paroxetine, fluoxetine, 
and sertraline appear relatively fast acting, with improvements compared to placebo CAPS 
scores within 2-12 weeks.61 
While benzodiazepines may be effective symptomatic treatments for insomnia, 
anxiety, and irritability associated with PTSD and helpful for treatment-resistant patients 
with severe symptoms, they have been shown to not effectively prevent PTSD or reduce 
core PTSD symptoms.62,63,64,65 Furthermore, benzodiazepines interfere with PE therapy 
because they suppress fear extinction.66,67 High doses of benzodiazepines taken in 
combination with opioids or alcohol can result in overdose and increase the risk of 
death.66,67 A 2013 meta-analysis found that benzodiazepines did not significantly reduce 
total PTSD symptom and severity scores (as measured by CAPS) compared to placebo.57 
 
                                                  Clinical Practice Guidelines 
 
For clinical practice, first-line recommended pharmacotherapies include the 
SSRIs sertraline, paroxetine, fluoxetine, citalopram, and fluvoxamine and the SNRI 
venlafaxine.38 If a patient has received maximally tolerated dosages of the first-line agent 
and an adequate duration of treatment, then it is advisable to switch to another agent 




none of these first-line agents are effective, a second-line agent is the next step of 
treatment.38 Although prazosin is recommended for nightmares not relieved by first-line 
medications, a recent randomized clinical trial in the VA found no significant 
improvement in the frequency and severity of nightmares in veterans treated with 
prazosin compared to those who received placebo.36,68 Other second-line agents include 
mirtazapine, nefazodone, and tricyclic antidepressants (imipramine, amitriptyline).38 
However, evidence for the effectiveness of second-line agents is not as strong as that for 
first-line medications because the latter agents effect the serotonergic receptors in the 
amygdala and other parts of the fear circuitry.38 Furthermore, many of these second-line 
medications have serious adverse effects, including hypotension, weight gain, and liver 
failure, and carry the risk of toxicity if taken in an overdose; for the SSRI or SNRI 
groups, the only main adverse effect is sexual dysfunction, most commonly delayed 
orgasm.38 
Benzodiazepines, opioids, atypical antipsychotics, and conventional 
antipsychotics are not recommended for the treatment of PTSD.21,38 Veterans with PTSD 
who were prescribed opioids were significantly more likely to experience opioid-related 
accidents and overdose, alcohol and nonopioid drug-related accidents and overdose, self- 
inflected injuries (suicide attempt), and violence-related injuries (gunshot wounds).69 
Atypical antipsychotics have serious side effects that include weight gain, tardive 
dyskinesia, anxiety, and metabolic syndromes such as hyperglycemia, diabetes, and heart 






Benzodiazepines are estimated to be prescribed to 30% to 74% of patients with 
PTSD.21 However, of all the pharmacotherapies prescribed to patients with PTSD, 
benzodiazepines (along with opioids) are a potentially addictive group of medications.37 
Benzodiazepines may be effective symptomatic treatments for insomnia, anxiety, and 
irritability associated with PTSD; they may be helpful for treatment-resistant patients with 
severe symptoms.21 Furthermore, benzodiazepines may reduce subjective anxiety in the 
short-term.37 One of the most common inhibitory neurotransmitters in the central nervous 
system is gamma aminobutyric acid (GABA).70 A GABA receptor complex contains sites 
for binding GABA as well as sites for binding other molecules that modulate GABA’s 
activity. The GABA receptor complex contains a central core permeable to chloride and 
other ions. When GABA binds with this complex, it induces conformational change, which 
increases the permeability of chloride ions.70 The resulting increase in the concentration of 
chloride ions in the postsynaptic neuron results in hyperpolarization, reducing the 
excitability of the neurons and producing an inhibitory effect in neuronal activities. 
Benzodiazepines increase the frequency with which the chlorine channel opens when 
GABA binds to its own site on the receptor complex.70 Thus, benzodiazepines increase the 
efficiency of GABA and allow it to produce a larger inhibitory effect. However, 
benzodiazepines may be ineffective for PTSD because the pathophysiology of PTSD 
differs from that of other anxiety disorders for which benzodiazepines have some 
efficacy.21 Locus ceruleus (brain stem) dysregulation is implicated in both panic disorder 
and PTSD; the hippocampus and amygdala are also implicated in PTSD.21 In addition, 




such as the prefrontal cortex that are already hypoactive in PTSD and which, when 
functioning properly, allow for various cognitive processes and modulation of the 
amygdala.21 Thus, anxiety in PTSD may be different from anxiety in other disorders and 
may require different treatments. 
Consistent evidence shows a lack of efficacy for the four core symptom clusters of 
PTSD, depression, and psychotherapy augmentation.21 Benzodiazepines have shown no 
significant improvement compared to placebo in treating PTSD.57 Furthermore, 
benzodiazepines are associated with specific problems in patients with PTSD. This 
includes worse overall PTSD symptom severity, psychotherapy outcomes, anxiety, 
aggression, substance abuse, and social functioning.21,57,62,63,70,71 For example, 
benzodiazepines interfere with psychotherapy because they suppress fear extinction.57 
High doses of benzodiazepines taken in combination with opioids or alcohol can result in 
overdose and increase the risk of death.66,67 
Benzodiazepines have been known to cause or worsen depression, dysphoria 
(dissatisfaction with life), and suicidal thoughts and behavior.21 These are all risk factors 
for increased suicide behavior. This is especially problematic because veterans are already 
at an elevated risk for suicide and depression is comorbid in 30-50% of patients with 
PTSD.72 Furthermore, benzodiazepine-induced depressive disorder can occur in 
individuals without a history of depression.73,74 Another major issue of benzodiazepines is 
that benzodiazepine dependence is a distinct problem in patients with PTSD; this is because 
most patients have PTSD symptoms that last for longer than three months.75 Discontinuing 
benzodiazepines in patients with benzodiazepine dependence results in decreased 




withdrawal symptoms that mimic and worsen PTSD symptoms (including anxiety, 
insomnia, agitation, perpetual disturbances, autonomic hyperactivity). Overall, although 
the therapeutic effects of benzodiazepines decrease with dependence, depression and 
impulsivity with high suicidal risk commonly persist.76 
The relationship between PTSD and suicide behavior can also be conceptualized 
through a behavioral avoidance model.77 This model represents a set of behaviors an 
individual undertakes to avoid or escape from unwanted emotional experiences.75 PTSD 
results in traumatic memories, dreams, and symptoms that are uncomfortable, which drives 
avoidance behavior; this includes suicide, which an individual will undertake in order to 
avoid the emotions caused by PTSD.77 Benzodiazepines serve the same function by 
allowing an individual to avoid/escape from emotional distress and pain.21 On the other 
hand, psychotherapies disrupt the avoidance process via exposure-based interventions; 
thus, because benzodiazepines function as avoidance, they can affect behavioral 
conditions, such as suicide, in veterans with PTSD. 
Potential explanations for benzodiazepines worsening PTSD outcomes include 
discontinuation symptoms, disruption of normal stress responses, avoidance of cognitive 
and emotional processing of trauma, and worsening of underlying PTSD 
pathophysiology.21 
Overall, benzodiazepines are ineffective for PTSD prevention and treatment, 
actually worsen overall PTSD, encourage dependence side effects, and worsen risk factors 





Gaps in Research and Public Health Impact 
 
Little is known about the comparative distribution of therapies veterans with 
PTSD receive in the VA and whether their symptoms improve as a result.33,35,71 Health 
care utilization is higher for veterans with PTSD compared to veterans without PTSD.78,79 
However, it is unclear how resource utilization differs between those who receive 
benzodiazepines versus no benzodiazepines.21,38,80,81 This is important to investigate 
because benzodiazepines are not effective for the treatment of PTSD and can worsen 
symptoms, causing veterans to seek more health care.21 Suicide behavior is one of the 
leading causes of mortality among veterans.81 While it is known that veterans with PTSD 
are more likely to have thoughts of hopelessness and suicidal ideation, it is unclear how 
suicide behavior differs between those who receive benzodiazepines versus no 
benzodiazepines.21,82,83 This is important to investigate because benzodiazepines can 
worsen depression, dysphoria, and suicidal thoughts, leading to an increased risk in 
suicide behavior.21,84-90 
Overall, despite the recommendation against their use, benzodiazepines are still 
prescribed for veterans in the VA. Thus, there remains a significant gap between research 
and actual clinical care. The findings of this large study will significantly strengthen the 
empirical evidence against benzodiazepines for the treatment of PTSD. The ultimate 





1. Describe utilization of psychotherapies and pharmacotherapies, including 




2. Evaluate the association between benzodiazepines and inpatient, outpatient, and 
emergency department (ED) utilization. 
Hypothesis: Benzodiazepines are associated with an increase in health care utilization. 
 
3. Evaluate the risk of benzodiazepines and suicide behavior. 
 





This is the first study to analyze a nationwide cohort of veterans with PTSD, with 
exposure being benzodiazepines versus no benzodiazepines use for PTSD. Furthermore, 
it is unclear how health care resource utilization and suicide behavior differs between 
benzodiazepine and nonbenzodiazepine treatments. By analyzing the outcomes of health 
care resource utilization and suicide behavior, this study investigates the difference in 














Randomized clinical trials (RCTs) are the gold standard study designs for 
estimating treatment effects.90 This is because random assignment to treatment 
theoretically balances observed and unobserved characteristics between both treatment 
and comparison groups. Patients who take different treatments are exchangeable; other 
than the intervention that is evaluated, their characteristics are the same.91 Thus, because 
these observed and unobserved variables are similar, the effect of treatment on outcomes 
can be estimated directly between the treatment and comparison groups. Unfortunately, 
RCTs are not always feasible due to ethical or practical reasons. Furthermore, RCTs are 
conducted in controlled circumstances, which limits the generalizability of results to day- 
to-day clinical practice.92 On the other hand, an observational study design aims to 
represent the real clinical situation.93 
However, in observational data, treatment assignment is not random.90 This leads 
 
to confounding bias, where measured and unmeasured characteristics of individuals are 
associated with the outcome and with the probability of receiving treatment. Thus, 
statistical methods must be employed to reduce confounding inherent in observational 




propensity scores provide a way to balance measured covariates across treatment and 
comparison groups.90 This will be a retrospective observational analysis of a cohort of 
veterans diagnosed with PTSD between January 1, 2001 and December 31, 2014, 
followed until December 31, 2015. Veterans will be followed from time of 





In observational studies, propensity scores are unknown and must be estimated 
from the data.91 The propensity score is the probability of receiving treatment conditional 
on baseline covariates.90 Consider the following for each subject i: a binary treatment 
indicator variable Ti, equal to 1 if a subject receives treatment and 0 if a subject does not 
receive treatment; a vector of observed baseline covariates Xi; and the outcome of interest 
Yi.
94,95 The propensity score, (Pi), for each subject i can be represented as the following: 
Pi = Pr (Ti = 1 | Xi ) (1) 
 
A logistic regression model is commonly used with treatment as the outcome and 
potential confounders, variables associated with outcome and exposure, as baseline 
covariates.90 
 
Propensity Score Assumptions 
 
The propensity score is a balancing score with two major assumptions: 
 
1. (Y1i, Y0i) ⊥ Ti | Xi 
 
2. 0 < Pr (Ti = 1 | Xi) < 1 
 




controlling for this vector, the potential outcomes Y1i and Y0i are independent of 
treatment status.96 The second one assumes that for each variable in the vector Xi, there is 
a positive probability of being both treated and untreated.96 
 
Variable Selection Strategies for Propensity Scores 
 
The omission of confounders from propensity scores results in effect estimates 
that are biased to the same degree and in the same direction as estimates obtained from 
omitting the same confounders in a conventional outcome model. The recommended 
variable selection strategy is to include all variables associated with an outcome in a 
propensity score regardless of their association with exposure.97 If a variable is related to 
the outcome but not the exposure, including it in the propensity score may help to reduce 
bias.90,98,99 On the other hand, controlling for variables that are associated with the 
exposure but not the outcome can increase the variance and bias of effect estimates; these 
variables should not be included in the propensity score.98,100 Thus, the variables to 
choose in the propensity score include confounders and variables associated with the 
outcome.98,100 
 
Propensity Score Methods 
 
There are four methods for using the propensity score to estimate treatment 
effects.101 These methods include stratification on the propensity score, covariate 
adjustment using the propensity score, matching on the propensity score, and weighting 
by the inverse probability of treatment (IPTW) using the propensity score. Stratification 




subjects within strata defined by the propensity score.94,,95,101 Five strata defined by the 
quintiles of the propensity score are commonly used. The effect of treatment on outcomes 
is estimated within each stratum. Propensity-score matching involves forming matched 
sets of treated and untreated subjects with similar values of the propensity score.94,95,101 A 
common approach is nearest neighbor pair-matching without replacement within 
specified calipers of the propensity score, often 0.2. Covariate adjustment using the 
propensity score is the most widespread propensity-score methods in the medical field.97 
In covariate adjustment, the treatment effect is estimated by the regression of the outcome 
on an indicator variable denoting treatment assignment and the propensity score. IPTW 
using the propensity score is the fourth method used to adjust for confounding.95 Inverse 
probability weights are calculated as the inverse conditional probability that a subject 
received the exposure he or she actually received. This is 1/(Propensity Score) for the 
exposed and 1/(1-Propensity Score) for the unexposed.97 Weighting by this quantity 
creates a synthetic population in which treatment assignment is independent of measured 
baseline covariates.97 
Propensity score matching has been shown to eliminate a greater portion of the 
systematic difference between the treated and untreated subjects compared with 
stratification on the propensity score and covariate adjustment using the propensity 
score.101-105 Monte Carlo simulations have been used to compare the performance of 
different propensity score methods.103 Matching on the propensity score and weighting 
using the inverse probability of treatment eliminated a greater degree of the systematic 
differences between treated and untreated subjects compared to stratification and 




comparable or marginally superior performance compared with propensity-score 
weighting.103 Thus, this study will use propensity score matching to balance measured 
covariates between benzodiazepine users and non-benzodiazepine users. 
 
 
Formation of Matched Sets 
 
After estimating propensity scores, propensity score matched sets of treated and 
untreated subjects must be formed.94,95,101 A matched set is a set of at least one treated 
subject and at least one untreated subject with similar propensity score values.94,95,101 The 
most commonly used method for the formation of these pairs is greedy matching using 
calipers of a specified width. For a given treated subject, the closest untreated subject 
within the specified caliper distance is selected for matching to this treated subject, even 
if the untreated subject would better have served as a match for a different treated 
subject.94,95,101 In this approach, a treated subject is randomly selected, and the untreated 
subject with the closest propensity score that lies within a fixed distance (the propensity 
score caliper) of the treated subject’s propensity score is selected for matching.94,95,101 In 
matching without replacement, once an untreated subject has been matched to a treated 
subject, that untreated subject is not available for consideration as a match for subsequent 
treated subjects.92,93,99 Recent research has found that matching on the logit of the 
propensity score using calipers of width 0.2 of the standard deviation of the logit of the 
propensity score resulted in estimates of treatment effect with lower mean squared error 






Once the propensity score matched sets of treated and untreated subjects have 
been created, the next step is to assess balance in baseline characteristics.94,95,101 The 
distribution of baseline characteristics should be similar between treated and untreated 
subjects within stratum matched on the true propensity score.94,95,101 The standardized 
difference is used to assess balance between treatment groups in the propensity score 
matched sample; it is the absolute difference in sample means divided by an estimate of 
the pooled standard deviation of the variable.94,95,101 The standardized difference 
represents the difference in means between the two comparison groups in units of 
standard deviation.94,95,101 The standardized difference does not depend on the unit of 
measurement nor is it influenced by sample size; it can be used to compare the relative 
balance of variables measured in different units.94,95,101 Thus, the standardized difference 
allows for the comparison of different treatment groups after the creation of propensity- 
matched pairs.92,93,99 Some authors have suggested that standardized differences of less 
than 0.10 (10%) likely denote a threshold of acceptable imbalance between treated and 
untreated subjects.94,95,101 Furthermore, the use of side-by-side box plots and quantile- 
quintile plots can be used to compare the distribution of continuous baseline covariates 
between exposed and unexposed subjects.94,95,101 
 
Estimation of Treatment Effect 
 
Once the propensity score has been estimated, a propensity score matched cohort 
has been created, and the balance in measured baseline variables between treated and 




treatment effect is possible.94,95,101 When a subject in the treatment group is matched to a 
corresponding subject in the control group with the same propensity score, the matched 
pair will have, in probability, the same value of covariate vector Xi. The average 
treatment effect (ATE) for the population is used to evaluate the expected effect on 
outcome if treatment assignment was random106: 
ATE = E(Y1 – Y0) = E(Y1) - E(Y0) (2) 
 
E(Y1) is the expected value for all subjects in the treatment group and E(Y0) is the 
expected value for all subjects in the control group.106 The ATE is an unbiased estimator 
of the treatment effect because the treatment group does not, on average, differ 
systematically from the control group on the covariate vector Xi. The ATE is directly 
estimated in the propensity-score matched cohort through a regression of outcome Yi on 





The data sources were the National Veterans Health Administration (VHA) 
Database and the VA/Department of Defense (DOD) Suicide Data Repository (SDR). 
The VHA database contains electronic health records of over 20 million veterans from 
the years 2000-2015; these veterans have sought health care at the 1400 VA facilities and 
152 medical centers throughout the United States.107 The VHA database includes the 
Corporate Data Warehouse (CDW) and MEDSAS datasets.107 As shown in Table 2, 
diagnosis, psychotherapies, pharmacotherapies, health care visits, and suicide behavior 
were all queried from different datasets within the CDW; demographics, confounders, 




database analyzed in this study was the VA/DOD SDR. This database includes the 
National Death Index Plus, which contains all-cause mortality for all service members 
who separated from active duty between the years 1979-2014; it also contains a current 
mortality archive on all users of VHA services from 2000-2014.110 All-cause mortality 
and suicide mortality were queried in the SDR. Scrambled social security numbers were 
used to link veterans in the different databases.110 The objectives of this study were 
addressed through an analysis of these databases. 
 
 
Study Population and Criteria 
 
The study population consisted of veterans with PTSD who are new users of 
benzodiazepines and treated at VA facilities throughout the United States. This study was 
an analysis of veterans diagnosed with PTSD between January 1, 2001 and December 31, 
2014 .111 Veterans are at a high risk for mental disorders and PTSD is the most 
commonly diagnosed mental disorder.111 A recent analysis of over 200,000 returning 
Operation Enduring Freedom/Operation Iraqi Freedom veterans found that rates of PTSD 
and other mental health disorders were increasing over time.110 Veterans with a diagnosis 
prior to January 1, 2001 were excluded. DSM-5 diagnostic criteria is currently used to 
diagnose PTSD.1 However, this diagnostic criteria is not easily identified in a structured 
data field. The International Classification of Diseases, Ninth Revision Clinical 
Modification (ICD-9-CM) codes was used to identify veterans with PTSD. The overall 
positive predictive value is 75% for at least one PTSD diagnosis (outpatient or inpatient) 
and 82% for at least two PTSD diagnoses (outpatient or inpatient) in VA databases.112 




truly have PTSD. Veterans with one ICD-9 code of 309.81 in any inpatient or outpatient 
encounter during the study time period were classified as having PTSD.112 
The creation of the cohort consisted of three distinct steps. The first step consisted 
of the cohort defining diagnosis, which will consist of one ICD-9 code for PTSD during 
the between January 1, 2001 and December 31, 2014. The second step involved inclusion 
of new users of benzodiazepines. A veteran was considered to be a new user of 
benzodiazepines if 1) he or she had one 30-day prescription of benzodiazepines in any 
health care encounter within 365 days after PTSD diagnosis, and 2) he or she had not 
used benzodiazepines at least six months prior to PTSD diagnosis. The third step in 
creating the cohort consisted of identifying VA utilizers and active VA users. A veteran 
was considered to be a VA utilizer if he or she had at least six months of VA care in any 
inpatient or outpatient setting at any point in time during the study period. In order to 
ensure veterans were active users of the VA, those without an encounter in any inpatient 
or outpatient setting within 12 priors prior to PTSD diagnosis were excluded from the 
cohort. The final eligible population consists of veterans diagnosed with PTSD between 
January 1, 2001 and December 31, 2014 who had at least six months of care and one VA 
encounter within twelve months prior to PTSD diagnosis. 
 
 
Sample Size and Power 
 
Sample size and power calculations were estimated with PS: Power and Sample 
Size software and based on the outcome of suicide behavior. With an outcome that can 
result in death, small effects are clinically relevant; a 10% difference in suicide is a very 




reduction in suicide within the next decade.111 Thus, in calculating sample size, the effect 
estimates were varied, including a 10% and 20% increase in risk for suicide behavior for 
veterans who are given benzodiazepines.111 The significance level was 0.05 and the 
power was 0.8. Because 30% to 74% of patients are estimated to receive 
benzodiazepines21, this range was varied in sample size calculations, including 30%, 
52%, and 74%. Furthermore, while there was no data on suicide behavior for veterans 
who are not given benzodiazepines, approximately 13% to 21% of all veterans exhibit 
suicide behavior.112, 113 Overall, as Table 3 reveals, the total required sample sizes ranged 
from 2,350 to 28,669 depending on the estimates for percent of veterans with suicide 
behavior, difference in suicide behavior, and prevalence of benzodiazepines among 
veterans. 
Ultimately, the sample size was large and consequently, the study sufficiently 
powered. A study on the utilization of VA nonmental health services among returning 
Afghanistan and Iraq veterans included 53,728 veterans diagnosed with PTSD between 
October 7, 2001 and March 31, 2007.111 Table 4 shows counts for VA patients diagnosed 
with PTSD, notes that include suicide in the title, and pharmacotherapies used to treat 
PTSD from 2000-2015. 
During the time period from 2000-2015, 2,096,018 patients were diagnosed with 
PTSD. Using parameter estimates of 13%, 17%, and 21% for percent of veterans with 
suicide behavior, a 10% and 20% increase in risk for suicide behavior for veterans who 
are given benzodiazepines, 30%, 52%, and 74% for veterans who are given 









The exposure consisted of two different treatment groups for veterans with PTSD, 
those who receive benzodiazepines versus those who do not. Patients were considered 
exposed for the entire study period if they were new users of benzodiazepines in the 
initial one-year period after diagnosis. An intention to treat (ITT) analysis in which 
exposure status as assumed throughout follow-up reflects the real-world clinical scenario 
because it admitted noncompliance and protocol deviations. Furthermore, ITT gave an 
unbiased estimate of the treatment effect because exclusion of noncompliant subjects and 
dropouts might create significant prognostic differences between the two treatment 
groups. This type of analysis also minimized type I error (false positive) due to its 
cautious approach and allowed for the greatest generalizability. However, the estimate of 
the treatment effect is generally conservative in ITT and thus more susceptible to type II 
error (false negative).116,118 
Medications were grouped by drug class. The no benzodiazepines group consists 
of a number of treatments, which includes psychotherapy, SSRIs, SNRI, antiadrenergic 
agent, tetracyclic antidepressant, serotonergic antidepressant, tricyclic antidepressant, 
opioids, atypical antipsychotics, and conventional antipsychotics. Other medications were 
similarly classified in order to adjust for them in models (psychotherapy users versus no 
psychotherapy users, SSRI users versus no SSRI users). The VA CDW contains data that 
includes treatments.108,109 Drug classes and names were used to identify medications in 
the outpatient drug and inpatient BCMA dispensed drug data sets; CPT codes were used 






The outcomes were health care utilization and suicide behavior. Health care 
utilization included mental health and nonmental health inpatient, outpatient, and ED 
visits. Stop codes and VA clinic codes with a diagnosis of PTSD were used to 
differentiate between nonmental and mental health visits. Visits were identified in the 
CDW in the outpatient and inpatient visit datasets. A stop code of 130 was used to 
differentiate between outpatient and ED visits. Suicide behavior was the other major 
outcome and included suicide completers, suicide attempters, and suicidal 
thoughts/ideation. Suicide behavior was identified multiple ways. One method was the 
presence of an Electronic Health Record note title with the term “suicide consult, event, 
attempt, flag, alert, warning, or report” in the VA CDW because these refer to current 
suicidal events while “suicide history” and “suicide follow-up” refer to suicidal events in 
the past.108,109 ICD-9 codes in the VA CDW was a second method used to identify suicide 
behavior. Table 5 shows these ICD-9 codes.118 The VA/DoD SDR contained data on 
suicide among veterans and was the third method used to identify completed suicides, 




Comorbidities were considered in this study. Traumatic brain injury, anxiety 
disorder, bipolar disorder, depression, alcohol abuse, opioid abuse, chronic pain, 
homelessness, smoking, and illicit drug use are other comorbid conditions commonly 
found in patients with PTSD.31,119-122 ICD-9 codes were used to identify comorbid 




such as age, gender, socioeconomic status, service percentage disabilities, race, and 
military sexual trauma were directly identified in the VHA. Age was categorized to 0-29, 
30-39, 40-49, 50-59, and 60+; gender to male and female; socioeconomic status to 
lowest, low, medium, and high; race to white, black or African-American, and other race. 
Service disabilities referred to disabilities that were incurred or aggravated during active 
military service; disability ratings were categorized to low percentage (0-29), medium 
percentage (30-59), and high percentage (60-100). 
Finally, it was not possible to differentiate between the two types of 
psychotherapy, CBT and PE, using CPT codes. Thus, single measures were used to 
capture both groups. Table 7 shows the CPT codes for psychotherapy.125,126 It should also 
be noted that these CPT codes are also unable to differentiate between CBT and other 
therapies, including supportive counseling and/or nonspecific therapies that are not 
expected to work for PTSD. 
 
 
Specific Variables Included in Propensity Score Model 
 
     Figure 2 is a directed cyclic graph (DAG) that identifies which variables should be 
assessed for inclusion in the propensity score model in the relationship between 
benzodiazepines and the health utilization and suicide behavior outcomes. The DAG 
demonstrated that anxiety disorder, bipolar disorder, depression, opioid abuse, alcohol 
abuse, chronic pain, antidepressants, and prazosin could be associated with the exposure, 
benzodiazepine treatment, and could also be associated with all of the outcomes.1,34,35, 70, 
118-119, 122,126-136 Thus, these comorbidities and medications were potential confounders and 




the outcomes included traumatic brain injury, gender, marital status, opioids, atypical 
antipsychotics, conventional antipsychotics, race, socioeconomic status, service 
percentage disabilities, age, military sexual trauma, smoking status, illicit drug use, 
homelessness, education, and employment; all but the last two were adjusted for in the 
propensity score model.1,33,36,57,90, 94,95, 137 There was no structured VA data on the risk 
factors of education and employment; thus, these two variables were not be adjusted for 
since more proximal risk factors were used. 
 
 
Statistical and Outcome Analysis 
 
Descriptive statistics were used to describe the different treatments for PTSD.137 
This includes patients who received a treatment (n, %), treatments per patient by class (n, 
median, IQR), fills per patient by class (n, median, IQR), median duration for oral and 
nonoral pharmacotherapies, median quantity for oral pharmacotherapies, patients who 
received an inpatient pharmacotherapy treatment (n, %), median duration for inpatient 
pharmacotherapy, patients who received a first or second (within thirty days of their first 
therapy) psychotherapy/pharmacotherapy (n, %), and most frequent overlapping therapies 
(n, %) . 
The impact of benzodiazepine use in veterans with PTSD was assessed in the 
matched cohort using regression models. Models included the treatment group as the 
primary independent variable and any additional variables that remained imbalanced 
between the groups in the matched sample.90,94,95 This doubly robust estimation combines 
a form of outcome regression with a model for exposure, the propensity score.138 When 




methods are unbiased only if the statistical model is correctly specified.138 The doubly 
robust estimator combines these two approaches such that only 1 of the 2 models needs to 
be correctly specified in order to obtain an unbiased effect estimate.138 Incidence rate 
ratios, rate differences, and hazard ratios were used to estimate the treatment effect. The 
incidence rate ratio is the ratio of the number of new cases per population at risk in given 
time period between two groups.139 The rate difference is the difference between the 
number of new cases per population at risk between two groups.139 The hazard ratio is the 
ratio of the hazard rates at any point in time between two groups.139 
Health care utilization (mental and nonmental health outpatient visits, inpatient 
hospitalizations, and ER visits) was analyzed with generalized linear models (GLM), 
which consists of the following components140: 
1. A random component specifying the conditional distribution of the 
response variable yi given the values of the explanatory variables 
a. Distribution is a member of an exponential family 
i. Poisson, Binomial, Gaussian, Inverse Gaussian, Gamma 
2. A linear predictor 
a. Linear function of regressors 
i. ni = a + b1xi1 + b2xi2 + ... + bkxik (3) 
3. A link function g(.) 
a. Transforms the expectation of the response variable, ui = E(Yi), to 
the linear predictor 
i. g(ui) = ni = a + b1xi1 + b2xi2 + ... + bkxik (4) 
However, in order to use GLM model, a number of assumptions must be assessed. 
GLM assumptions include140: 
 
1. Dependent variable assumes a distribution from an exponential family 





2. Linear relationship between the transformed response in terms of the link 
function and the explanatory variables 
a. Scatter plot to see if nonlinearity is present 
3. Homogeneity of variance of the residuals 
a. Residual is difference between observed value of the dependent 
variable, yi, and the estimated value, ŷi 
b. Variance of residuals should be constant 
i. Graphically, plot of residuals against estimated values 
should show no pattern 
ii. Statistically, White Test of homogeneity 
4. Normality of residuals 
a. Residuals should be normally distributed 
i. Graphically, plot of residuals against normal quantiles 
should lie along 45-degree line 
ii. Statistically, Shapiro-Wilk W-Test of normality 
 
In addition, log-binomial or modified Poisson regression was used to directly 
estimate risk differences.139 Log-binomial regression was used unless model convergence 
is an issue.141 In that case, modified Poisson regression, which is Poisson regression with 
robust error variance, was used.140 Modified Poisson regression has a major assumption 
that the variance equals the mean: 
Var (y) = φ*E (y) = φ*µ, where φ=1 (5) 
This assumption can be assessed statistically through the scale factor, the scaled deviance 
and the scaled Pearson.140 If either scale factor is greater than one, then a negative 
binomial model was used to account for this over-dispersion where the variance is not 




Because it was a time to event outcome, suicide-related outcomes were estimated 
through hazard ratios from a Cox Proportional Hazards regression model.140 The major 
assumption of a Cox model is that of proportional hazards.140 This means that the 
survival curves for two groups must have hazard functions that are proportional over 
time.140 Proportionality was assessed though a plot of the residuals against time by 
exposure group (benzodiazepine users vs. nonbenzodiazepine users). Median survival 
times in all of the suicide outcomes were also reported and differences in overall survival 
between the two groups were assessed through log-rank tests. All statistical analyses 
were performed using SAS V9.3 (Cary, NC) and Stata 13 (College Station, TX), 






































versus No Benzodiazepines 
Outcome: Inpatient 
Hospitalizations, Outpatient 
Visits, ED Visits, Suicide 
Behavior 
Confounders: Anxiety 
Disorder, Bipolar Disorder, 
Depression, Opioid Abuse, 
Alcohol Abuse, Chronic Pain, 
Antidepressants, Prazosin 
Possible Instruments: Drug 
Representative Visits, 
Prescriber Education/Training 
Risk Factors: Traumatic Brain 
Injury, Gender, Marital Status, 
Opioids, Atypical and 
Conventional Antipsychotics, 
Race, Socioeconomic Status, 
Service Percentage Disabilities, 
Age, Military Sexual Trauma, 






Table 2. Data Sources for Variables 
 
Variable Data Source 
Diagnosis Outpatient Diagnosis, Inpatient Diagnosis 
Psychotherapies Outpatient Procedure, Inpatient CPT 
Procedure 
Pharmacotherapies Outpatient Prescription Fill, Bar Code 
Medication Administration, Dispensed 
Drug 
Demographics, Confounders, and Risk 
Factors 
Patient Demographics, Outpatient 
Diagnosis, Inpatient Diagnosis 
Health Care Visits Outpatient Visits, Inpatient Visits 
Suicide Behavior Outpatient Diagnosis, Inpatient Diagnosis 
Mortality, Including All-Cause and 
Suicide 




























13% 10% 30% 7, 770 18,130 25,900 
13% 10% 52% 11,413 10,535 21,952 
13% 10% 74% 21,215 7,454 28,669 
13% 20% 30% 2,007 4,683 6,690 
13% 20% 52% 2,967 2,739 5,706 
13% 20% 74% 5,548 1,950 7,498 
17% 10% 30% 5,655 13,194 18,849 
17% 10% 52% 8,303 7,664 15,967 
17% 10% 74% 14,437 5,419 19,856 
17% 20% 30% 1,457 3,400 4,857 
17% 20% 52% 2,152 1,987 2,350 
17% 20% 74% 4,023 1,412 5,435 
21% 10% 30% 4,346 10,141 14,487 
21% 10% 52% 6,377 5,886 12,263 
21% 10% 74% 11,850 4,160 16,010 
21% 20% 30% 1,117 2,606 3,723 
21% 20% 52% 1,647 1,521 3,168 








Patients with PTSD 2,096,018 
Suicide in TIU note 591,676 
SSRI 1,294,778 
SNRI 318,794 
Antiadrenergic Agent 416,169 
Tetracyclic Antidepressant 397,908 
Serotonergic Antidepressant 60,185 
Tricyclic Antidepressant 227,918 
Benzodiazepines 882,351 
Opioids 1,063,824 




Table 5. Suicide Behavior with ICD-9 Codes118 
 
Suicide Behavior ICD-9 
Suicide and Self-Inflicted Poisoning by 
Solid or Liquid Substances 
E950.0-E950.9 
Suicide and Self-Inflicted Poisoning by 
Gases in Domestic Use 
E951.0-E951.1, E951.8 
Suicide and Self-Inflicted Poisoning by 
Other Gases and Vapors 
E952.0-E952.1, E952.8-E952.9 
Suicide and Self-Inflicted Injury by 
Hanging, Strangulation, and 
Suffocation 
E953.0-E953.1, E953.8-E953.9 
Suicide and Self-Inflicted Injury by 
Submersion 
E954 
Suicide and Self-Inflicted Injury by 
Firearms, Air Guns, and Explosives 
E955.0-E955.7, E955.9 
Suicide and Self-Inflicted Injury by 
Cutting and Piercing Instrument 
E956 
Suicide and Self-Inflicted Injury by 
Jumping From High Place 
E957.0-E957.2, E957.9 
Suicide and Self-Inflicted Injury by 
Other and Unspecified Means 
E958.0-E958.9 
Late Effects of Self-Inflicted Injury E959 




Table 6. Comorbidities with ICD-9 Codes123,124 
 
Comorbidity ICD-9 
Traumatic Brain Injury 850.0-850.5, 850.9, 851.0-851.9, 852.0- 
852.5, 853.0, 853.1, 854.0, 854.1 
Anxiety Disorder 300.00, 300.01, 300.02, 300.09 
Bipolar Disorder 296.00-296.06, 296.40-296.46, 296.50- 
296.56, 296.60-296.66, 296.7, 296.80 
Depression 296.20-296.26, 296.30-296.36, 296.82, 
311 
Alcohol Abuse 305.00, 305.01, 305.02, 305.03 
Opioid Abuse 305.50, 305.51, 305.52, 305.53 
Chronic Pain 338.21, 338.22, 338.28, 338.29 
Homelessness V60.0 
Smoking Status V15.82, 305.1 




Table 7. Psychotherapy with CPT Codes125,126 
 
Psychotherapy CPT Code Before 2013 CPT Code 2013+ 
Talk Therapy for 30 
Minutes 
90804/90810 90832 
Talk Therapy for 45 
Minutes 
90806/90812 90834 
Talk Therapy for 60 
Minutes 
90806/90814 90837 
Crisis, for 60 Minutes NA 90839 












Objective 1 Results 
 
The results of this section report the size of the cohort with PTSD, the distribution 
of therapies (including duration, number, and fills) for this cohort, inpatient exposure, and 
the most frequent overlapping therapies. 
The number of veterans with one ICD-9 code for PTSD between January 1, 2001 
and December 31, 2014 was 1,445,934 (Figure 3). The next step involved excluding 
121,000 patients who used benzodiazepines within six months prior to PTSD diagnosis; 
this resulted in a cohort of 1,324,934. Afterwards, 7,589 patients who did not have 6+ 
months of VA care in any inpatient or outpatient setting at any point in time during the 
study were excluded, reducing the cohort to 1,317,345. The final step involved excluding 
183,144 patients who did not have an encounter in any inpatient or outpatient setting 
within 12 months prior to PTSD diagnosis. As shown in Figure 3, removing these non- 
active VA users resulted in a final cohort of 1,134,201 veterans. Of these, 80,832 patients 
were users of benzodiazepines - at least a 30-day supply, no use within six months prior 






Baseline characteristics were captured 12 months prior to PTSD diagnosis (Table 
8). In the cohort with PTSD (1,134,201), the median age was 53.12 with an IQR of 23.69. 
90.60% of veterans were male and 66.90% were white. Regarding comorbidities, 13.41% 
of veterans had anxiety disorder, 12.64% had diabetes, 10.04% were smokers, 8.85% had 
depression, 7.98% had chronic pulmonary disease, and 5.95% had alcohol abuse. The 
prevalence of depression for the entire cohort with no time restrictions was 32.87% 
(372,866). 47.33% of veterans were married, 20.47% were divorced, 18.60% were single, 
and 2.28% were widowed. The most common periods of service were the Vietnam Era, 
Persian Gulf Era, and post-Vietnam, with respective percentages of 43.87, 39.43, and 
8.46. Post-Vietnam refers to veterans with a first service entry date after the Vietnam Era 
ended, ie May 7, 1975. 59.56% of veterans had low service percentage disabilities, 
17.18% had high service percentage disabilities, and 14.04% had low service percentage 
disabilities. The most common age categories were 60+, 50-59, 0-29, and 40-49, with 
respective percentages of 28.38%, 25.82%, 13.77%, and 13.06%. Lastly, socioeconomic 
status was evenly spread throughout the veteran population, with 24.21% being of lowest 




Distribution of Psychotherapies and Pharmacotherapies 
 
All psychotherapies and pharmacotherapies were captured one year after PTSD 
diagnosis (Figure 4). Annualized duration and quantity were also captured one year after 
PTSD diagnosis. Oral treatment consisted of tablets, capsules, oral solution and oral 
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concentrate. Nonoral treatment consisted of injection, intravenous, suppository, syringe, 
gel, and solution. Because solution can refer to oral or injectable drugs, a conservative 
approach of grouping solution with nonoral pharmacotherapies was taken. 
For the distribution on the use of recommended psychotherapies and 
pharmacotherapies in the cohort with PTSD, 46.76% of veterans received psychotherapy, 
26.78% received SSRIs, 6.75% received prazosin, 6.07% received mirtazapine, and 4.31% 
received venlafaxine (Table 9). The median number of psychotherapy sessions was 5, 
ranging from 1 for 60 min crisis to 7 for group therapy (Figure 5). The median number of 
distinct SSRI treatments was 1; the median number of fills was 7. The median number of 
fills for all pharmacotherapies ranged from 4 to 8 (Figure 6). The median duration for oral 
and nonoral SSRIs was 90 days, with a large variation (respective interquartile ranges are 
210 and 150); the median duration for all other pharmacotherapy classes, both oral and 
nonoral, was equal or shorter compared to SSRIs (with the exception of nonoral prazosin) 
(Figure 7). The median quantity for oral SSRIs was 45, which was less than or equal to all 
other pharmacotherapies except mirtazapine, which had a quantity of 30 (Figure 8). 
For the distribution on the use of not recommended pharmacotherapies in the cohort 
with PTSD, 7.53% of veterans received atypical antipsychotics, 7.07% received 
benzodiazepines, 6.95% received opioids, and 0.34% received conventional 
antipsychotics; the respective median number of distinct treatments for all classes was 1 
(Table 10). In Figure 6, the median number of fills for benzodiazepines was 9; the 
respective median number of fills for conventional antipsychotics, atypical antipsychotics, 
and opioids was 7, 8, and 13. In Figure 7, the median duration for oral and nonoral 
benzodiazepines was 90 days, with a large variation (respective interquartile range is both 
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150). The median duration for all other pharmacotherapy classes, both oral and nonoral, 
was equal or shorter compared to benzodiazepines. As shown in Figure 8, the median 
quantity for benzodiazepines was 60, which was greater than or equal to all other 
pharmacotherapies except opioids, which had a quantity of 100. 
 Inpatient Pharmacotherapy Exposure 
A total of 306,166 veterans with PTSD had at least one inpatient encounter, with a 
median length of 4 days and an IQR of 6 (Table 11). As shown in Figure 9, the total 
number of veterans who received benzodiazepines for at least 30 days was 15,260 (1.34% 
of total cohort); the median duration of benzodiazepine exposure is 55 days. The overall 
distribution of inpatient treatment percentages ranged from 0.027% (nefazodone) to 
2.64% (opioids); median duration ranged from 49 days (tricyclic antidepressants) to 61 
days (atypical antipsychotics). 
         Distribution of First or Second Therapies in Cohort with PTSD 
 In the cohort of veterans with PTSD, 63.41% received a first or second 
psychotherapy/pharmacotherapy within one year after PTSD diagnosis (Table 12, Figure 
10). In this group, 37.32% of veterans received psychotherapy, 17.08% received SSRIs, 
6.16% received opioids, 4.14% received atypical antipsychotics, and 4.01% received 
benzodiazepines. 
Approximately 49.6% of veterans received either only one psychotherapy or 
pharmacotherapy and nothing else within 30 days of their first therapy (Table 13). In this 
subgroup, 25.84% of veterans received psychotherapy, 11.44% received SSRIs, 4.50% 
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received opioids, 2.53% received benzodiazepines, and 2.48% received atypical 
antipsychotics. 
Approximately 13.77% of veterans received a second (overlapping) 
psychotherapy/pharmacotherapy within 30 days of their first therapy (Table 14). In this 
subgroup, 11.48% of veterans received psychotherapy, 5.63% received SSRIs, 1.67% 
received opioids, 1.66% received atypical antipsychotics, and 1.47% received 
benzodiazepines. 
Most Frequent Overlapping Therapies in Cohort with PTSD 
The most frequent overlapping therapies in the cohort with PTSD included 
psychotherapies, psychotherapy/SSRI, SSRI/prazosin, SSRI/atypical antipsychotics, and 
SSRI/benzodiazepines; the percentage of veterans who received these respective 
combinations are 4.39%, 3.11%, 0.64%, 0.52%, and 0.49% (Table 15, Figure 11). The 
majority of combinations include two psychotherapies and all combinations included 
either one psychotherapy or one SSRI. 
Objective 2 Results 
The results of this section describe the cohort with PTSD before and after 
propensity score matching and the models used to analyze health care utilization. The 
health care utilization incidence rate ratios and incidence rate differences between 
benzodiazepine users and nonbenzodiazepine users are then reported. 
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Propensity Score Matching 
Before propensity score matching, there were 80,832 benzodiazepine users and 
1,053,369 nonbenzodiazepine users (Figure 12). After 1:2 matching, 891,705 patients 
have been excluded; the final propensity score matched cohort consists of 242,493 
veterans, with 80,831 benzodiazepine users and 161,662 non-benzodiazepine users. In the 
propensity score model, all variables were represented through dummy coding (0 or 1). 
A histogram of the distribution of the propensity scores before and after matching 
shows that the mean (0.0796), median (0.0695), mode (0.080), and maximum (0.287) are 
now the same (Figure 13, Figure 14). As shown in Table 16, before propensity score 
matching, chi-square tests for confounders and risk factors between the benzodiazepine 
and non-benzodiazepine users indicated significant differences in almost all of these 
variables. However, after matching, in Table 17, the number of variables with a 
statistically significant difference between them has decreased; although the chi-square 
test results indicate that some differences remain, none of these differences are clinically 
meaningful. Furthermore, as shown in Table 18, all of the standardized differences have 
decreased after propensity score matching. Before matching, the (dummy) variables 
male, divorced, single, separated, widowed/widower, unknown marital status, white, 
medium service percentage disabilities, high service percentage disabilities, age 0-29, age 
30-39, age 50-59, age 60+, and homeless all had standardized differences greater than
0.1. A plot of the standardized differences (Figure 15) before matching reveals that three 
variables have a very high standardized difference: medium service percentage 
disabilities (0.337), high service percentage disabilities (0.432), and homeless (0.294). In 









The health care utilization outcomes are hospitalizations, emergency department 
(ED) visits, general outpatient visits, mental health outpatient visits, substance abuse 
outpatient visits, and total mental health outpatient visits (sum of mental health outpatient 
visits and substance abuse outpatient visits). Modified Park test coefficients indicated that 
the suggested distributions are either Poisson or Gamma (Table 19). The histogram for 
ED visits is skewed to the right due to the large proportion of zeroes (62.4%). Thus, a 
Gamma distribution was be used to model this outcome; it was modeled with a Poisson 
regression. However, as shown in Table 20, the scaled Deviance and scaled Pearson 
values for ED visits are 5.40 and 12.40. Thus, in order to account for this overdispersion 
(variance>mean), a negative binomial model was used for ED visits. 
There is overdispersion present in general outpatient, mental health outpatient, 
substance abuse outpatient, and total mental health outpatient visits because the 
respective scaled Deviance and scaled Pearson values are 23.75, 35.43; 40.87, 163.99; 
23.59, 148.88; 52.94, 182.31 (Table 20). Thus, a negative binomial model was used for 
these distributions. Finally, a Poisson model was used to model hospitalizations because 
overdispersion is not present in that distribution; the scaled Deviance and scaled Pearson 
values are 0.21 and 2.08. 
Due to the presence of a large number of zeroes in all of the outcomes, a Vuong 
test was run to determine whether a zero-inflated negative binomial/Poisson or standard 




indicate that a zero-inflated negative binomial model should be used for general 
outpatient, mental health outpatient, substance abuse outpatient, and total mental health 
outpatient visits while a nonsignificant p-value indicates that a standard negative 
binomial model should be used for ED visits; a significant p-value indicates that a zero- 
inflated Poisson model should be used for hospitalizations (Table 22). 
 
 
IRRs and IRDs for Health Care Visits 
 
The health care utilization incidence rate ratios (IRR) and incidence rate 
differences (IRD) are all statistically significant between veterans who receive 
benzodiazepines and those who do not receive benzodiazepines except for substance 
abuse outpatient visits (Table 23, Figure 17). The IRRs are all higher for benzodiazepine 
users; this includes inpatient hospitalizations (1.27), ED visits (1.16), general nonmental 
health outpatient visits (1.18), total mental health outpatient visits (1.37), and mental 
health outpatient visits (1.48). An IRR of 1.2718 means that benzodiazepine users have 
27.18% more hospitalizations than nonbenzodiazepine users over a six-year time period. 
The respective IRDs are all higher for benzodiazepine users; this includes inpatient 
hospitalizations (0.02), ED visits (0.27), general outpatient visits (3.48), total mental 
health outpatient visits (5.75), and mental health outpatient visits (5.47). An IRD of 
0.0271 means that benzodiazepine users have on average 0.0271 additional 
hospitalizations than nonbenzodiazepine users over a six-year time period. Although the 
IRR (1.07) and IRD (0.27) are higher for benzodiazepine users, the p-values are not 
significant for either (respective values of 0.074 and 0.069). Thus, there is not a 




those who not receive benzodiazepines for substance abuse outpatient visits. 
 
 
Objective 3 Results 
 
The results of this section report counts and hazard ratios for the suicide behavior 
outcomes using ICD-9 codes, note titles, and the Suicide Data Repository. The suicide 
outcomes were analyzed through the Suicide Data Repository, ICD-9 codes, and Suicide 
Note Titles. Cox proportional hazards regression was used to analyze the various suicide 
outcomes. As shown in Figures 18, 19, 20, 21, 22, 23, 24, and 25, plots of the Schoenfeld 
residuals against time indicate that residuals for the benzodiazepine group and non- 
benzodiazepine group are parallel and do not cross for almost all of the suicide outcomes. 
Thus, the proportional hazards assumption of the Cox model is not violated. For suicide 
and self-inflicted injury using note titles, the Schoenfeld residuals for the two groups only 
cross at the very end; furthermore, it the number of suicide events are low, 24 for 
veterans who receive benzodiazepines and 22 for patients who do not receive 
benzodiazepines. A Cox model will still be used to model this suicide outcome. The 
hazard rate ratios and 95% confidence intervals for all of the suicide outcomes are 
presented in Figure 26. 
 
 
Suicide Defined Through the Suicide Data Repository 
 
Using the Suicide Data Repository, there were all-cause death counts for 26,841 
(11.06%) patients in the entire cohort (Table 24). The all-cause mortality hazard ratio 
between benzodiazepine users and non-benzodiazepine users is 1.86 (Table 25). The 




nonbenzodiazepine users are 349 (2.41%) (Table 24). The suicide mortality hazard ratio 
is 2.73 (Table 25). The VA Clinical Practice Guidelines for PTSD were implemented in 
2010. The percentage of benzodiazepine users who had suicide as cause of death before 
and after 2010 is 1.70% and 1.97%; the respective percentages for non-benzodiazepine 
users are 0.81% and 1.60% (Table 24). As shown in Table 25, in the Cox model adjusted 
for 2010, the suicide mortality hazard ratio is now 2.33. 
 
 
Suicide Behavior Defined Through ICD-9 Codes 
 
As shown in Table 26, using ICD-9 codes, 6.45% of veterans who received 
benzodiazepines and 4.45% of veterans who do not receive benzodiazepines exhibited 
suicide behavior. Of patients who received benzodiazepines, 5.65% exhibited suicidal 
thoughts or ideation, and 1.74% had a self-inflicted injury or attempted suicide; of 
patients who did not receive benzodiazepines, 4.05% exhibited suicidal thoughts or 
ideation, and 0.99% had a self-inflicted injury or attempted suicide (Table 26). The 
hazard ratio between benzodiazepine users and non-benzodiazepine users is 1.56 for 
suicide behavior, 1.51 for suicide thoughts/ideation, and 1.84 for suicide/self-inflicted 
injury (Table 27). 
 
 
                                         Suicide Behavior Defined Through Note Titles 
 
As shown in Table 28, using note titles, 2.17% of benzodiazepine users and 
1.13% of nonbenzodiazepine users exhibited suicide behavior. Of patients who received 
benzodiazepines, 2.14% exhibited suicidal thoughts or ideation, and 0.03% had a self- 




1.12% exhibited suicidal thoughts or ideation, and 0.01% had a self-inflicted injury or 
attempted suicide (Table 28). The hazard ratio between benzodiazepine users and non- 
benzodiazepine users is 1.97 for suicide behavior, 1.96 for suicide thoughts/ideation, and 
2.27 for suicide/self-inflicted injury (Table 29). 
 
In 2008, suicide behavior note titles began to be implemented as “Suicide 
Behavior Reports.” However, this was not consistently implemented at many VA 
facilities because notes with other titles are still used. As shown in Table 30, 0.64% of 
benzodiazepine users and 0.47% of nonbenzodiazepine users had a note title for suicide 
behavior before 2008. Of patients who received benzodiazepines, 0.63% exhibited 
suicidal thoughts or ideation, and 0.01% had a self-inflicted injury or attempted suicide; 
of patients who did not receive benzodiazepines, 0.46% exhibited suicidal thoughts or 
ideation, and 0.01% had a self-inflicted injury or attempted suicide (Table 30). 
Approximately 1.53% of benzodiazepine users and 0.67% of nonbenzodiazepine users 
had a note title for suicide behavior after 2008. Of patients who received 
benzodiazepines, 1.51% exhibited suicidal thoughts or ideation, and 0.02% had a self- 
inflicted injury or attempted suicide; of patients who did not receive benzodiazepines, 
0.66% exhibited suicidal thoughts or ideation, and 0.01% had a self-inflicted injury or 
attempted suicide (Table 30). As shown in Table 31, in the Cox model adjusted for 2008, 
the respective the hazard ratio between benzodiazepine users and nonbenzodiazepine 
users is 1.84 for suicide behavior, 1.83 for suicide thoughts/ideation, and 2.10 for 
suicide/self-inflicted injury (Table 31). Median survival times are presented in Table 32 
for benzodiazepine users and nonbenzodiazepine users for all of the suicide outcomes. 




users (log-rank test p-value<0.0001). 
 
 
                                                          ICD-9 Codes or Note Titles 
 
Kappa statistics were used to evaluate agreement between ICD-9 codes and note 
titles. The kappa statistic is 0.2069 for suicide behavior, 0.1967 for suicide thoughts and 
ideation, and 0.0042 for suicide and self-inflicted injury. The kappa values indicated only 
slight agreement between the ICD-9 codes and note titles. Thus, ICD-9 codes and note 
titles were not combined into a composite outcome. 
As shown in Table 33, using ICD-9 codes or note titles, 7.51% of benzodiazepine 
users and 5.03% of nonbenzodiazepine users exhibited suicide behavior. Of patients who 
received benzodiazepines, 6.82% exhibited suicidal thoughts or ideation, and 1.77% had a 
self-inflicted injury or attempted suicide; of patients who did not receive benzodiazepines, 
4.69% exhibited suicidal thoughts or ideation, and 1.01% had a self-inflicted injury or 
attempted suicide (Table 33). The hazard ratio between benzodiazepine users and non- 
benzodiazepine users is 1.60 for suicide behavior, 1.57 for suicide thoughts/ideation, and 














Figure 4. Percentage Overall Use of Psychotherapies and Pharmacotherapies for Veterans 




















































































































                   
          
          
            
           
           
           
           


































































Figure 10. Percentage Use of First or Second (Overlapping) Psychotherapies and 




























Figure 11. Percentage Use of Most Frequent Overlapping Psychotherapies and 































Figure 12. Propensity Score Matched Cohort Flow Chart 
Step 1: Number of Patients before Matching with a 
Propensity Score 
 















Step 2: 1:2 Propensity Score Matching 
 
80,831 benzodiazepine users 



















































































































Table 8. Baseline Characteristics in Cohort with PTSD (n=1,134,201)* 
 
Variable Mean/N SD/% 
Age (Median, IQR) 53.12 23.69 
Gender   
Male 1,027,908 90.60% 
Female 102,660 9.05% 
Unknown/Missing 3,633 0.32% 
Race   
White 758,832 66.90% 
Black or African-American 222,261 19.59% 
Declined to 118,504 10.40% 
Answer/Unknown/Missing   
Others 34,604 3.05% 
Comorbidities   
Anxiety Disorder 152,181 13.41% 
Smoking 113,904 10.04% 
Depression† 100,463 8.85% 
Alcohol Abuse 67,518 5.95% 
Bipolar Disorder 32,719 2.89% 
Chronic Pain 14,070 1.24% 
Illicit Drug Use 11,415 1.01% 
Military Sexual Trauma 9,525 0.83% 
Homeless 7,107 0.63% 
Traumatic Brain Injury 6,684 0.60% 
Opioid Abuse 5,166 0.45% 
Charlson Comorbidities   
Diabetes 143,474 12.64% 
Chronic Pulmonary Disease 90,583 7.98% 
Diabetes with Chronic 28,359 2.50% 
Complications   
Cerebrovascular Disease 25,169 2.21% 
Congestive Heart Failure 16,212 1.42% 
Peptic Ulcer Disease 7,379 0.65% 
Rheumatologic Disease 5,988 0.52% 
Mild Liver Disease 5,675 0.50% 
Peripheral Vascular Disease 4,882 0.43% 
AIDS 3,883 0.34% 
Dementia 3,143 0.27% 
Hemiplegia or Paraplegia 2,234 0.19% 
Myocardial Infarction 2,188 0.19% 
Renal Disease 1,190 0.10% 
Moderate or Severe Liver 919 0.08% 
Disease   
Marital Status   
Married 536,841 47.33% 
Divorced 232,277 20.47% 
Single 210,988 18.60% 
Unknown/Missing 128,161 11.29% 
Widowed/Widower 25,913 2.28% 




Table 8. Continued 
 
Period of Service   
Vietnam Era 497,665 43.87% 
Persian Gulf 447,232 39.43% 
Post-Vietnam 95,980 8.46% 
Others 93,212 8.21% 
Unknown/Missing 112 0.01% 
Service Percentage Disabilities   
Low 675,604 59.56% 
High 194,918 17.18% 
Medium 159,254 14.04% 
Unknown 104,425 9.21% 
Age   
60+ 321,891 28.38% 
50-59 292,950 25.82% 
0-29 156,728 13.77% 
40-49 148,176 13.06% 
30-39 126,674 11.16% 
Unknown 465 0.04% 
Socioeconomic Status   
Lowest 274,620 24.21% 
Low 233,239 20.56% 
Medium 196,597 17.33% 
High 196,390 17.31% 
Unknown 233,355 20.57% 
*Captured 12 months prior to PTSD diagnosis 
†Post-Vietnam refers to veterans with a first service entry date after the Vietnam Era ended, i.e. May 7, 





Table 9. Overall Use of Recommended Psychotherapies/Pharmacotherapies in Cohort 













































 NA NA NA 
Talk Therapy 288,877 1,803,175     
for 45 (25.46%) (2,5) 
Minutes   
Talk Therapy 220,382 848,699 (2, 1) 
for 30 (19.43%)  
Minutes   
  4,136,962 
Group Therapy 193,483 (7,16) 
 (17.05%)  
  476,036 (2,3) 
Talk Therapy 113,568  
for 60 (10.01%)  
Minutes  2,806 (1,0) 
Crisis, for 60 2,311 
 
Minutes (0.20%)  
SSRIs 303,747 
(26.78%) 
474,836 (1,0) 2,565,993 
(7, 15) 
90 (210) 90 (150) 45 (45) 














81,875 (1,0) 357,226 
(7, 14) 






104,314 (1,0) 354,782 
(4, 7) 






84,912 (1,0) 350,096 
(5, 10) 






12,934 (1,0) 83,268 (8, 
15) 










39,999 (1,0) 188,814 
(6, 14) 
90 (150) 90 (180) 90 (70) 




*Psychotherapies are not mutually exclusive to each other 
†All treatments captured one year after PTSD diagnosis; oral consists of tablets, capsules, oral solution, and 
oral concentrate; non-oral consists of injection, intravenous, suppository, syringe, gel, and solution (since 
“solution” can refer to oral or injectable drugs, it is safe to keep this grouped with non-oral) 




Table 10. Overall Use of Not Recommended Psychotherapies/Pharmacotherapies in 












































115,098 (1,0) 702,201 
(9, 21) 
90 (150) 90 (150) 60 (60) 














205,607 (1,1) 1,254,847 
(13, 29) 
60 (180) 60 (120) 100 (40) 



























152,224 (1,0) 714,537 
(8, 17) 
90 (150) 60 (120) 30 (30) 










5,113 (1,0) 26,981 (7, 
17) 
90 (150) 90 (180) 60 (60) 






*Annualized duration and quantity captured one year after PTSD diagnosis; oral consists of tablets, 
capsules, oral solution, and oral concentrate; non-oral consists of injection, intravenous, suppository, 
syringe, gel, and solution (since “solution” can refer to oral or injectable drugs, it is safe to keep this 




Table 11. Inpatient Pharmacotherapy Exposure in Cohort with PTSD 
 
Treatments* Total Number 
of Patients, N 






Stay in Days, 
IQR 
(N=306,166) 
   4 (6) 
Recommended 
Treatments 




SNRI 5,629 (0.49%) 55  
Antiadrenergic Agent 4,429 (0.39%) 51  
Tetracyclic 
Antidepressant 
6,194 (0.54%) 57  
Serotonergic 
Antidepressant 
307 (0.027%) 52  
Tricyclic Antidepressant 1,457 (0.12%) 49  
Not Recommended 
Treatments 












2,097 (0.18%) 60  
*Annualized duration (at least thirty days) captured one year after PTSD diagnosis for oral, which consists 




Table 12. First or Second Psychotherapy/Pharmacotherapy in Cohort with PTSD 
 
Recommended Treatments Total Number of Patients, N (%) 
Psychotherapy* 423,350 (37.32%) 
Talk Therapy for 45 Minutes 
Talk Therapy for 30 Minutes 
Group Therapy 
Talk Therapy for 60 Minutes 


































Not Recommended Treatments  































Table 13. First Psychotherapy or Pharmacotherapy in Cohort with PTSD 
 
Recommended Treatments Total Number of Patients, N (%) 
Psychotherapy* 293,132 (25.84%) 
Talk Therapy for 45 Minutes 
Talk Therapy for 30 Minutes 
Group Therapy 
Talk Therapy for 60 Minutes 


































Not Recommended Treatments  































Table 14. Second Psychotherapy or Pharmacotherapy in Cohort with PTSD 
 
Recommended Treatments Total Number of Patients, N (%) 
Psychotherapy† 130,218 (11.48%) 
Talk Therapy for 45 Minutes 
Talk Therapy for 30 Minutes 
Group Therapy 
Talk Therapy for 60 Minutes 


































Not Recommended Treatments  



























*Patients who received another treatment for PTSD within 30 days of their first treatment 




Table 15. Most Frequent Overlapping Therapies in Cohort with PTSD 
 
Combination N (%) 
Psychotherapies 49,890 (4.39) 
Psychotherapy/SSRI 35,386 (3.11) 
SSRI/Prazosin 7,312 (0.64) 
SSRI/Atypical Antipsychotics 6,001 (0.52) 




Table 16. Comparison of Confounders and Risk Factors Before Matching 
 



































































































































































































































Race    
White 700,444 (66.50%) 58,388 (72.23%)  
Black or African- 210,727 (20.01%) 11,534 (14.27%)  
American    
Others 32,295 (3.07%) 2,309 (2.86%)  
Declined to 110,173 (10.43%) 8,601 (10.64%)  
Answer    
/Unknown/Missing    
   <0.0001 
Socioeconomic    
Status    
Lowest 256,181 (24.32%) 18,439 (22.81%)  
Low 216,197 (20.52%) 17,042 (21.08%)  
Medium 182,290 (17.31%) 14,307 (17.70%)  
High 182,643 (17.34%) 13,747 (17.01%)  
Unknown 216,058 (20.51%) 17,297 (21.40%)  




Table 16. Continued 
 
Service Percentage    
Disabilities    
Low 628,347 (59.65%) 47,257 (58.46%)  
Medium 148,805 (14.13%) 10,449 (12.93%)  
High 180,678 (17.15%) 14,240 (17.62%)  
Unknown 95,539 (9.07%) 8,886 (10.99%)  
   <0.0001 
Age    
0-29 161,264 (15.31%) 15,364 (19.01%)  
30-39 128,362 (12.19%) 12,296 (15.21%)  
40-49 154,423 (14.66%) 12,503 (15.47%)  
50-59 306,544 (29.10%) 21,089 (26.09%)  
60+ 302,328 (28.70%) 19,563 (24.20%)  
Unknown 448 (0.04%) 17 (0.02%)  
   <0.0001 
Military Sexual    
Trauma, N (%)    
No 16,202 (1.54%) 1,508 (1.87%)  
Yes 8,733 (0.83%) 792 (0.98%)  
Unknown 1,028,434 (97.63%) 78,532 (97.15%)  
   <0.0001 
Smoking Status, N    
(%)    
No 947,693 (89.87%) 72,604 (89.82%)  
Yes 105,676 (10.03%) 8,228 (10.18%)  
   0.180 
Illicit Drug Use, N    
(%)    
No 1,042,924 (99.01%) 79,862 (98.80%)  
Yes 10,445 (0.99%) 970 (1.20%)  
   <0.0001 
Homelessness, N (%)    
No 951,049 (90.29%) 71,620 (88.60%)  
Yes 6,781 (0.64%) 326 (0.40%)  
Unknown 95,539 (9.07%) 8,886 (10.99%)  





Table 17. Comparison of Confounders and Risk Factors After Matching 
 



































































































































































































































Race    
White 116,331 (71.96%) 58,387 (72.23%)  
Black or African- 23,395 (14.47%) 11,534 (14.27%)  
American    
Others 4,912 (3.04%) 2,309 (2.86%)  
Declined to 17,024 (10.53%) 8,601 (10.64%)  
Answer    
/Unknown/Missing    
   0.008 
Socioeconomic    
Status    
Lowest 36,997 (22.89%) 18,438 (22.81%)  
Low 34,022 (21.05%) 17,042 (21.08%)  
Medium 28,557 (17.66%) 14,307 (17.70%)  
High 27,489 (17.00%) 13,747 (17.01%)  
Missing 34,597 (21.40%) 17,297 (21.40%)  
































































































































Table 18. Standardized Differences Before and After Propensity Score Matching 
 
Variable Standardized Difference 
in Cohort (n=1,134,201) 
Standardized 
Difference in Matched 
Sample (n=242,493) 
TBI 0.008 0.008 
Anxiety Disorder 0.081 0.006 
Bipolar Disorder 0.023 0.018 
Depression 0.003 0.017 
Alcohol Abuse 0.088 0.016 
Opioid Abuse 0.017 0.015 
Chronic Pain 0.012 0.013 
SSRI 0.015 0.006 
SNRI 0.025 0.017 
Prazosin 0.011 0.017 




Opioids 0.237 0.001 
Male 0.124 0.005 



















Race   
White 
Black or African-American 
Others 









































Table 18. Continued 
 
Socioeconomic Status   
Lowest 0.034 0.002 
Low 0.026 0.001 
Medium 0.018 0.001 
High 0.004 0 
Smoking 0.005 0.011 
Homeless 0.294 0.004 
Illicit Drug Use 0.020 0.016 














Hospitalizations 1.13 Poisson 237,884 
(98.1%) 




1.48 Poisson 36,494 (15.0%) 
Mental Sum 1.03 Poisson 92,353 (38.1%) 
Outpatient Visits    
Mental Outpatient 1.07 Poisson 88,255 (36.4%) 
Visits    
Substance Abuse 1.04 Poisson 211,809 




Table 20. Scaled Deviance and Scaled Pearson Values 
 
Health Care Utilization 
Outcome 
Scaled Deviance Scaled Pearson 
Hospitalizations 0.21 2.08 
ED Visits 5.40 12.40 
General Outpatient Visits 23.75 35.43 
Total Mental Outpatient 52.94 182.31 
Visits   
Mental Outpatient Visits 40.87 163.99 
Substance Abuse 23.59 148.88 




Table 21. Vuong Test Results 
 
Health Care Utilization Outcome P-Value 
Hospitalizations 0.000 
ED Visits 0.424 
General Outpatient Visits 0.000 
Total Mental Outpatient Visits 
Mental Outpatient Visits 







Table 22. Model Used for Health Care Utilization Outcomes 
 
Model Outcome(s) 
Zero-Inflated Poisson Hospitalizations 
Zero-Inflated Negative Binomial General Outpatient, Mental, Substance 
Abuse, Mental Sum Outpatient Visits 




















































Mental Health 1.4895 <0.0001 5.4729 <0.0001 
Outpatient (1.4128,  (4.5468,  
 1.5703)  6.3990)  
Substance 1.0749 0.074 0.2773 (- 0.069 
Abuse (0.9923,  0.0232,  












All-Cause Death 12,387 (15.13%) 14,454 (8.94%) 26,841 (11.06%) 
Suicide as Cause 456 (3.68%) 349 (2.41%) 805 (2.99%) 
of Death    
Before 2010 211 (1.70%) 117 (0.81%) 328 (1.22%) 




Table 25: Hazard Rate Ratios Using Suicide Data Repository 
 
Suicide Outcome Hazard Ratio (HR) P-Value 
All-Cause Death 1.8634 (1.8071, 1.9214) <0.0001 
Suicide as Cause of Death 2.7399 (2.4001, 3.1279) <0.0001 
Suicide as Cause of 
Death, Adjusted for 2010 













Total, N (%) 
Suicide Behavior* 5,286 (6.45%) 7,206 (4.45%) 12,492 (5.15%) 
Suicide Thoughts 4,628 (5.65%) 6,555 (4.05%) 11,183 (4.61%) 
and Ideation    
Suicide and Self- 1,432 (1.74%) 1,615 (0.99%) 3,047 (1.25%) 
Inflicted Injury    
*Suicide thoughts and ideation, suicide and self-inflicted injury are not mutually exclusive to each other 
within benzodiazepines and no benzodiazepines groups (patients can exhibit both ICD-9 codes) 
Note: With no time restrictions, 6.90% of veterans in the cohort (16,740) have suicide behavior, 6.00% 









Hazard Ratio (HR) P-Value 
Suicide Behavior 1.5643 (1.4737, 1.6604) <0.0001 
Suicide Thoughts and 1.5177 (1.4144, 1.6156) <0.0001 
Ideation   
Suicide and Self- 1.8467 (1.6446, 2.0736) <0.0001 















Total, N (%) 
Suicide Behavior 1,779 (2.17%) 1,837 (1.13%) 3,616 (1.49%) 
Suicide Thoughts 1,755 (2.14%) 1,815 (1.12%) 3,570 (1.47%) 
and Ideation    
Suicide and Self- 24 (0.03%) 22 (0.01%) 46 (0.02%) 
Inflicted Injury    
Note: With no time restrictions, 2.01% of veterans in the cohort (4,896) have suicide behavior, 1.98% 










Hazard Ratio (HR) P-Value 
Suicide Behavior 1.9707 (1.8266, 2.1260) <0.0001 
Suicide Thoughts and 1.9664 (1.8199, 2.1247) <0.0001 
Ideation   
Suicide and Self- 2.2767 (1.7900, 2.8956) <0.0001 













Total, N (%) 
Suicide Behavior 
Before 2008 
524 (0.64%) 759 (0.47%) 1,283 (0.52%) 
Suicide Thoughts 516 (0.63%) 748 (0.46%) 1,264 (0.51%) 
and Ideation    
Suicide and Self- 8 (0.01%) 11 (0.01%) 19 (0.01%) 
Inflicted Injury    
Suicide Behavior 
After 2008 
1,255 (1.53%) 1,078 (0.67%) 2,333 (0.95%) 
Suicide Thoughts 1,239 (1.51%) 1,067 (0.66%) 2,306 (0.94%) 
and Ideation    
Suicide and Self- 16 (0.02%) 11 (0.01%) 27 (0.01%) 
Inflicted Injury    
 
 




Hazard Ratio (HR) P-Value 
Suicide Behavior 1.8397 (1.6816, 2.0127) <0.0001 
Suicide Thoughts and 1.8351 (1.6749, 2.0105) <0.0001 
Ideation   
Suicide and Self- 2.1069 (1.6540, 2.6840) <0.0001 






Table 32: Median Survival Time in Days 
 






All-Cause Death 1091 1353 <0.0001 
Suicide as Cause of Death 605 938 <0.0001 
ICD-9 for Suicide Behavior 461 1023 <0.0001 
ICD-9 for Suicide Thoughts 521 1105 <0.0001 
ICD-9 for Suicide 421 900 <0.0001 
Note Title for Suicide Behavior 287 861 <0.0001 
Note Title for Suicide 
Thoughts 
287 860 <0.0001 
Note Title for Suicide 294 963 <0.0001 
ICD-9 or Note Title for Suicide 
Behavior 
434 1008  
<0.0001 
ICD-9 or Note Title for Suicide 
Thoughts 
480 1065  
<0.0001 













Total, N (%) 
Suicide Behavior* 6,149 (7.51%) 8,145 (5.03%) 14,294 (5.89%) 
Suicide Thoughts 5,587 (6.82%) 7,583 (4.69%) 13,170 (5.43%) 
and Ideation    
Suicide and Self- 1,454 (1.77%) 1,632 (1.01%) 3,086 (1.27%) 
Inflicted Injury    
Note: The kappa statistic is 0.2069 for suicide behavior, 0.1867 for suicide thoughts and ideation, and 
0.0042 for suicide and self-inflicted injury. The kappa values indicate only slight agreement between the 
ICD-9 codes and note titles. Thus, the two methods will not be combined. 
*Suicide thoughts and ideation, suicide and self-inflicted injury are not mutually exclusive to each other 











Hazard Ratio (HR) P-Value 
Suicide Behavior 1.6074 (1.5192, 1.7006) <0.0001 
Suicide Thoughts and 1.5714 (1.4783, 1.6704) <0.0001 
Ideation   
Suicide and Self- 1.8527 (1.6536, 2.0756) <0.0001 












Strengths/Limitations and Comparison to Prior Literature 
 
   This study was the first to describe the use of both psychotherapies and 
pharmacotherapies for veterans with PTSD in the national VA setting. No prior literature 
has looked at the total and median number of treatments/fills per class and described 
median treatment duration and quantity in such a large cohort. There is limited literature 
on the distribution of pharmacotherapies for veterans with PTSD.142,143 Prior literature 
found a similar distribution as in my study for some of the pharmacotherapies; SSRIs are 
the most frequently prescribed followed by the SNRI venlafaxine. Benzodiazepines were 
found to be the next highest, around 30.5%; this is in contrast to my study, in which 
7.07% of veterans receive benzodiazepines within one year after PTSD diagnosis.142,143 
Thus, the prevalence of benzodiazepines is lower in my study. There are a myriad of 
reasons for this difference. First, previous studies did not exclude patients who used 
benzodiazepines six months prior to PTSD diagnosis.142,143 The application of this criteria 
resulted in excluding 121,000 patients in my study, which more than halved the total 
percentage of veterans who received benzodiazepines. These patients were excluded to 
ensure the effect of exposure on health outcomes after PTSD diagnosis and not on prior 




benzodiazepine use for only the year 2009 while another study was longitudinal but 
reported annual benzodiazepine use from 1999 to 2009; this method to capture exposure 
differs from that employed in my study, in which benzodiazepine use was measured at 
one point in time - twelve months after PTSD diagnosis.142,143 Third, my study included 
six different benzodiazepines, which was lower than that included in other research.142,143 
The six benzodiazepines - lorazepam, clonazepam, alprazolam, diazepam, temazepam, 
and chlordiazepoxide HCL - were included because they are the most commonly 
prescribed or longest used (chlordizaepoxide HCL) benzodiazepines to specifically treat 
PTSD.1,21,38,68,144 Fourth, prior studies required no minimum days’ supply; on the other 
hand, my study required veterans to have at least a 30 days’ supply of 
benzodiazepines.140,141 
Furthermore, this study was the first to evaluate the association between veterans 
who received benzodiazepines with health care utilization and suicide mortality. Another 
strength is that the study population consisted of a large number of veterans exposed to 
benzodiazepines, which ensured adequate power. While comparability between exposed 
and nonexposed is difficult to achieve in a retrospective cohort, the existence of 
observable systematic differences between the two treatment groups was reduced through 
propensity scores. In addition, this method preserved the exposed group, separated the 
analysis phase from the design phase, and reduced the likelihood of bias from iterative 
model building. 
This study had some limitations. The major limitation of propensity score 
matching is that it only accounts for measured confounders and only to the extent that 




VHA on education and employment. There was no attempt made to adjust for these two 
risk factors along with any other unobserved confounders and thus, some unmeasured 
confounding may be present in this study. However, more proximal risk factors were 
used and an exhaustive search of the literature ensured all potential confounders and risk 
factors were included in the propensity score model. 
A second limitation of this study is information bias that stems from potential 
mismeasurement of study variables. ICD-9 codes were used to classify veterans by 
mental health status. However, the overall positive predictive value is 75% for at least 
one PTSD diagnosis in VA databases; this means that 75% of the individuals with at least 
one PTSD diagnosis in the VA databases truly have PTSD.112 There could also be 
misclassification of the outcome, particularly suicide behavior. Nondifferential 
misclassification would bias results towards the null (HR=1). The strongest outcome for 
suicide behavior is death by suicide as determined by the SDR. On the other hand, there 
is unreliability in coding and documentation for ICD-9 codes and suicide behavior note 
titles. ICD-9 codes only include patients who presented to a VA for medical treatment 
following a suicide attempt or crisis; similarly, the presence of a suicide behavior note 
title depends on a veteran’s decision to present and disclose self-injury at a VA visit and 
also a clinician’s reliability in entering a note title. Nonetheless, similar patterns in the 
hazard ratios across note titles, ICD-9 codes, and the SDR suggest that the results present 
in the first two are not largely attributable to errors or limitations in those methods. 
There are two more limitations in this study. First, the population limits external 
validity to a specific cohort of veterans; male veterans who were diagnosed with/sought 




are not generalizable to all veterans with PTSD. However, veterans who did seek some 
care outside (and inside) the VA were included if they did meet the cohort eligibility 
criteria. Second, patients were considered exposed for the entire study period if they were 
new users of benzodiazepines in the initial one-year period after diagnosis. While 
exposure status can vary over time, the initiation period was limited to one year; the ITT 
analysis adjusted for variables at the time of drug initiation through propensity scores that 
included risk factors and confounders in the year prior to PTSD diagnosis. Furthermore, 
an ITT analysis reflects the real-world setting and minimizes type I error. 
There are three final limitations of this study. The first is misclassification of non- 
VA medication use. Patients who use benzodiazepines may have received this medication 
outside of the VA but not within the VA. However, there is an incentive for veterans to 
seek care at the VA because co-pays for the majority of medications, including 
benzodiazepines, are much lower in the VA than outside. Second, PTSD symptom 
severity was not adjusted for in the propensity score model. There were two reasons for 
this. First, there is no structured data field in the VHA that captures symptom severity; 
scales such as the Posttraumatic Diagnostic Scale (PDS) that measure symptom severity 
are not consistently implemented. Second, severity was indirectly adjusted for through 
the inclusion of comorbidities such as bipolar disorder, anxiety disorder, and depression. 
Finally, baseline suicide behavior was not adjusted for in the propensity score model. 
However, the standardized differences of 0.012 for suicide thoughts/ideation and 0.008 
for suicide attempts/self-inflicted injury in the matched cohort indicate that these 






The overall distribution of therapies in the cohort is similar to that outlined in the 
2010 VA PTSD Clinical Practice Guidelines.38,143 However, after the first-line 
psychotherapies and SSRIs, the not recommended benzodiazepines (7.07%) and atypical 
antipsychotics (7.53%) have the highest prevalence. The median number of 
benzodiazepine fills is nine (IQR of 21) and the median duration is three months. The 
distribution of first or second therapies is similar to that seen in the overall distribution, 
with the not recommended benzodiazepines (4.01%) and atypical antipsychotics (4.14%) 
having the highest prevalence after the first-line psychotherapies and SSRIs. The third- 
most frequent overlapping therapy (0.49%) includes benzodiazepines in conjunction with 
SSRIs. 
Veterans with PTSD who received benzodiazepines have significantly higher 
incidence rate ratios for almost all types of health care visits. This includes 
hospitalizations (1.27), ED (1.16), general outpatient (1.18), total mental outpatient 
(1.37), and mental outpatient visits (1.48). The suicide mortality hazard rate between 
benzodiazepine users and nonusers is 2.73; regardless of whether suicide behavior was 
defined through ICD-9 codes or Note Titles, all hazard ratios indicated that 
benzodiazepines are associated with a greater risk for suicide behavior, suicide thoughts, 
and attempted suicide. 
The evidence from this study reveals that benzodiazepines, at approximately 7%, 
are one of the pharmacotherapies prescribed for patients with PTSD and that they are 
associated with greater health care utilization and suicide outcomes. Most importantly, 




veterans with PTSD and that ultimately, prescribers should weight the benefits and risks 
 
– especially the almost three-fold increase in suicide death – when deciding to prescribe 









Table 35: PTSD Diagnoses Definitions from DSM III to DSM-5 (1980-2013) 
 
DSM-III (1980) DSM-III-R 
(1987) 







-Events that are 








Exposure to a traumatic 
event 
-Person experienced, 
witnessed, or was confronted 
with an event that involved 
actual or threatened death, 
serious injury, or threat to 
the physical integrity of 
oneself or others 
-Response had to involve 
fear, helplessness, or horror 
Exposure to a traumatic 
event 
-Exposure to actual or 
threatened death, serious 
injury, or sexual violence in 
one or more of the following 
ways: 
1. Directly experiencing the 
traumatic events 
2. Witnessing, in person, the 
event(s) as it occurred to others 
3. Learning that the traumatic 
event(s) occurred to a close 
family member or friend. In 
cases of actual or threatened 
death of a family member or 
friend, the event(s) must have 
been violent or accidental. 
4. Experiencing repeated or 
extreme exposure to aversive 


























-Acting as if traumatic event 
were recurring-Physiological 
reactivity upon stimulus 
exposure 
One Intrusion Symptom 




-Intense or prolonged distress 
after exposure to traumatic 
reminders 
-Marked physiological 




Table 35: Continued 
 











-Efforts to avoid 
thoughts of the 
traumatic event 
-Efforts to avoid 








-Efforts to avoid 
thoughts of the 
traumatic event 
-Efforts to avoid 





One Avoidance Symptom 
-Trauma-related thoughts or 
feelings 
-Trauma related external 
reminders (people, places, 
conversations, activities, 




































Two Negative Alterations 
in Cognition and Mood 
Symptoms 
-Dissociative Amnesia 
-Persistent negative beliefs 
-Persistent distorted blame 




interest in (pre-traumatic) 
significant activities 




-At Least One 
Month 
Duration 
-At Least One Month 
Two Arousal Symptoms 
-Irritable or aggressive 





 Significant Distress 
or Functional 
Impairment 
Significant Distress or 
Impairment in Some 
Realm of Functioning 
Duration 
-At Least One Month 
   Significant Distress or 
Impairment in Some 
Realm of Functioning 
   Not Due to Medication, 
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